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Chapter 1 Introduction 
True stem cells have the potential to produce any type of cell in the body. In recent years, 
advances in stem cell biology enabled us to think of these cells as powerful tools in 
regenerative medicine. In this thesis, their potential and use in musculoskeletal tissue 
engineering will be discussed. 
The discovery of stem cells is closely related to the study of radiation illness and bone marrow 
transplantation. In the 1940s and 1950s numerous experiments were carried out to find out how 
ionizing radiation affects the body, and how its negative effect can be avoided. In an animal 
study in 1949 Jacobson et al. found that shielding the spleen prevented death from lethal does 
of radiation. Later, similar effect was achieved by subsequent injection of spleen or bone 
marrow.(Lorenz et al., 1951) Soon after evidence was found, that the blood contains cells that 
are able to rescue humans or animals from bone marrow failure.(Gatti et al., 1968; Pillow et 
al., 1966) They were later termed hematopoietic stem cells, and it has been shown, that even a 
single cell is able to repopulate the bone marrow, and regenerate the complete hematopoietic 
system.(Osawa et al., 1996) 
Since then, it has been shown that stem cells exist not only in hematopoietic tissues, but in fact 
most, if not all tissues in the human body. Virtually, all multicellular animal groups have been 
shown to harbor stem cells. (Bode, 2004) So far it has been proven in various vertebrates 
(birds, amphibians and fish), as well as in other bilaterians (Drosophila and Planaria). There is 
evidence for the existence of stem cells in primitive multicellular animal groups: sponges and 
Cnidarians.(Bode, 2004) It is meaningless to talk about stem cells in unicellular animals, and 
they are present in all major groups of multicellular animals. 
It seems that they emerged simultaneously with cell differentiation. Traditionally, cell lineages 
have been divided into two groups: germ line and somatic cells. Germ line cells produce 
gametes; they are characterized by telomerase activity, and are potentially immortal. Most 
somatic cells are differentiated to fulfill specific roles. Certain tissues require constant 
production of cells (skin, intestines, blood), and these are provided by various progenitor cell 
types. 
Somatic cells undergo several divisions during their differentiation and are exposed to many 
mutagenic environmental factors. Therefore, the integrity of their genetic material is decreasing 
with age and depends on how far down they are located in the developmental hierarchy. 
Telomere shortening limits the life span of most somatic cells to about 40 cell divisions (<80). 
This mechanism is suggested to have developed in long-lived animals in order to prevent 
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accumulating too many mutations in the genetic material of somatic cells by many divisions, 
and thus to suppress tumors.(Chang et al., 2001) 
In case of tissue damage it is important to recruit healthy cells with high capacity to divide in 
order to quickly replace the cells that were lost, in order to regenerate the injured areas. Most 
probably this is the main function of adult stem cells. They were shown to play a role in 
replacing and recruiting/activating regenerative cells.(Ohnishi et al., 2007; Sasaki et al., 2008) 
Stem cells stop dividing relatively early during embryonic development, and have high 
telomerase activity. Therefore their division must be suppressed to avoid tumor (teratoma) 
formation, and should only be re-activated when new cells are needed. It was also reported, 
that intestinal stem cells – which divide more than 1000× during their lifetime – protect their 
genome by retaining old DNA strands through unknown mechanisms. (Potten et al., 2002) 
This way, the daughter cells receive the newly synthesized strands, which may contain copying 
errors. This is preferred, since the resulting progenitor cells will rapidly differentiate and will 
be shed into the intestines. 
Simple as it my sound, it is not easy to define a stem cell. To avoid confusion with other cell 
types (progenitors, cancer cells, etc.) stemness must be defined. A cell has to fulfill three 
criteria to be called a stem cell: 
Self-renewal: The ability to asymmetrically divide into an identical cell and a daughter 
cell, which produces differentiated cells. 
Clonality: Single cells are able to create more identical stem cells under appropriate 
conditions. Some definitions also include longevity here, which means that stem cells 
should be able to divide indefinitely, or at least many more times than a differentiated 
cell (at least 160 divisions). 
Potency: A cell that is able to give rise to multiple types of cells 
These guidelines are generally accepted, however, as with any definition, grey areas and 
exceptions exist. 
Stem cells can be divided into three groups based on their differentiation potential. Totipotent 
cells are the zygote, and its early descendants. They are able to produce both embryonic and 
extraembryonic cell types. In mammals, for example, they participate in embryo and placenta 
formation. During the blastula state, an inner cell mass forms. Its cells are not able to produce 
extraembryonic cell types anymore, therefore they are termed pluripotent. As the organism 
develops further, some stem cells’ potential becomes even more restricted, and can only 
produce the cell types of a single germ layer or tissue. These cells are called multipotent (or 
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tissue specific), because they are still able to give rise to several cell types. At the end of the 
line stand the progenitor cells, which are not stem cells, because they are only able to produce a 
single cell type. 
Due to their potential, stem cells hold a promise in human therapy. Totipotent cells are rarely 
investigated; much of the research is done using pluripotent cells. For example, they can be 
isolated from the inner cell mass of the developing embryo. Until recently, this was the only 
convenient source of pluripotent stem cells. 
Takahashi et al. managed to prepare induced pluripotent stem (IPS) cells from human skin cells 
by introducing four defined factors: Oct4, Sox2, c-Myc and Klf4.(Takahashi and Yamanaka, 
2006) Later it was found that two of these factors are dispensable in certain cell types where 
the others are suitably expressed, and over-expression of Oct4 together with either Klf4 or c-
Myc was sufficient.(Kim et al., 2008) High levels of these factors are readily able to transform 
cells, but the retroviral transduction further increases the tumorigenic potential. This risk can 
be reduced by alternative delivery methods, for example by using the piggyBAC 
transposone.(Kaji et al., 2009; Woltjen et al., 2009) The ability to induce pluripotent cells from 
(in theory) any cell in the body is surely going to have enormous importance in regenerative 
medicine. 
However the proliferation of both embryonic stem (ES) cells and IPS cells is difficult to 
regulate, and they are potentially able to cause tumors and teratomas. Some pluripotent cells 
have already been used in clinical therapy, for example to treat brain disorders. Fetal neural 
stem cells were shown to have caused tumors in a stem cell treated patient for the first time 
recently.(Amariglio et al., 2009) Therefore, a better understanding of these cells is necessary 
before actual clinical application.  
Stem cells also exist in the adult organism. The proliferative capacity of adult stem cells is 
lower and their differentiation potential is more restricted than that of embryonic stem cells. 
Their subtypes are distinguished based on their differentiation potential. So far endodermal, 
mesenchymal, hemangioblastic and neural stem cells have been described. In this study, we 
focus on the mesenchymal stem cells. Although their potential is limited, their use is 
considered much safer than ES cells and they have been used in clinical therapy already.(Lee et 
al., 2009) Also, it is easy to acquire autologous preparations of these cells, which makes their 
use even more convenient.(Quarto et al., 2001) 
The non-adherent hematopoietic cells from bone marrow were the first adult stem cells 
described.(Becker et al., 1963; Wolf and Trentin, 1968) These cells needed a special 
microenvironment for growth, which was provided by adherent marrow stromal cells in the 
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culture flask.(Dexter et al., 1973; Friedenstein et al., 1970) It was discovered that these 
adherent cells were capable of producing bone, and a part of them are uncommitted, and need 
osteogenic stimuli to do that.(Haynesworth et al., 1992)  
This was a good indication that the marrow stromal cells were potential stem cells themselves. 
Later, evidence of differentiation into chondrocytes and adipocytes was also 
gathered.(Johnstone et al., 1998; Owen, 1985; Yoo et al., 1998) It was still possible that the 
marrow contains a mixture of progenitor cell populations, each responsible for one lineage of 
differentiation. Clear evidence of multipotential of marrow stromal cells was presented by 
Pittenger et al. in 1999, who showed chondrogenic, osteogenic and adipogenic differentiation 
of clonally isolated cells.(Pittenger et al., 1999) The cells are also able to differentiate into 
tenocytes and myocytes.(Ferrari et al., 1998; Young et al., 1998) Recently, they have also been 
shown to contribute to healing skin injuries by differentiating into several cell types in 
vivo.(Sasaki et al., 2008) Although, it may be argued that cell fusion occurred in these animals. 
Based on these findings, the multipotent fraction of adherent marrow stromal cells can be 
termed mesenchymal stem cells (MSCs).  
Stem cells with similar potential can be acquired from other mesenchymal tissues. So far, they 
have been isolated from bone, fat, muscle, cartilage, synovium and tendon (see Table 1-1). 
Table 1-1 Summary of MSC sources 
Bone marrow (Pittenger et al., 1999) 
Muscle (Lee et al., 2000) 
Synovium (Bari et al., 2001) 
Fat (Erickson et al., 2002; Zuk et al., 2002) 
Periosteum (Fukumoto et al., 2003) 
Bone (Porter et al., 2009; Sakaguchi et al., 2004)
Cartilage (Dowthwaite et al., 2004) 
Tendon (de Mos et al., 2007) 
Mesenchymal stem cells are generally isolated by plastic adherence, and represent a 
heterogeneous cell population. These cells have been characterized, but despite several 
attempts, no single cell surface marker was found to determine MSCs. Usually, a set of 
proteins is used to characterize them (see Table 1-2).(Battula et al., 2008) 
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Table 1-2 MSC cell surface markers 
Stem cells are able to help the regeneration of various 
tissues in the human body. The cells act through three 
basic mechanisms. First, they are able to home in on 
the injured area, proliferate and differentiate into the 
required cell types. Second, they are releasing 
cytokines and growth factors, which stimulate the 
growth and/or matrix production of the surrounding 
cells. Third, they can fuse with other cells, and then 
divide again, thereby turning into a differentiated, 
proliferating cell and contributing to healing 
response.(Herzog and Krause, 2006) 
Many tissues in the living organism heal naturally. 
This is especially true to those that are frequently damaged: skin, bone, mouth epithelium. The 
tissue’s own cells actively contribute to matrix formation, and its stem cells are able to produce 
more cells when necessary. In some cases tissue regeneration is not possible. There may be 
various underlying causes: 
Extended tissue damage, for example: Large areas of burnt skin, critical size defects in 
bone 
Patient condition, e.g. healing of osteoporotic bone 
Terminally differentiated cells or highly sophisticated tissue architecture, e.g. damaged 
brain structures, eyes, and articular cartilage. 
The repair of complex structures is very costly, and these tissues are usually able to fulfill their 
function past the reproductive age, therefore, there was no selective pressure, which would 
evolve repair mechanisms. Their failure is an increasing problem in today’s aging society in 
developed countries. 
Since the natural healing response is not adequate, it is important to find ways to enhance 
healing, or reconstruct tissues or organs artificially. Tissue engineering is a branch of 
regenerative medicine, which aims to achieve this goal. 
This approach uses a combination of competent cells and a supportive matrix to create an 
artificial replacement for damaged tissues or organs. The point of this is to produce a self-
sustaining, long-lasting piece of tissue. In order to reach this goal, it is necessary to stimulate 
the cells to produce the necessary secreted proteins (matrix, growth factors, and proteases) In 
the case of stem cells they need to be differentiated into tissue-specific cell type(s). When 
Name CD# Presence 
Endoglin 105 + 
ecto-5’ nucleotidase 73 + 
ALCAM 166 + 
b1-integrin 29 + 
HCAM 44 + 
Thy-1 90 + 
STRO-1  + 
PTPRC 45 - 
(none) 34 - 
prominin 1 133 - 
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mature cells are used, they may need stimuli to maintain their phenotype. These stimuli can be 
biochemical, biomechanical, basically any environmental factor that helps to achieve the goal 
of the tissue engineering process. 
After cell isolation it may be necessary to culture the cells on the template matrix before 
implantation. Tissue engineering may be done in situ like in autologous chondrocyte 
transplantation (ACT),(Brittberg et al., 1994) or may have an in vitro preparation phase. This 
latter strategy was used in a recent study, where tissue-engineered vascular grafts were 
fabricated using fibroblasts to produce walls, and endothelial cells for inner lining.(McAllister
et al., 2009) 
In this thesis, the use of MSCs for the tissue engineering of two musculoskeletal tissues will be 
described. First, the osteogenic potential of statins is investigated for bone repair. These 
substances have been postulated to induce the differentiation of MSCs, but there is some 
controversy in the outcome of the experiments. This study tries to explain this by comparing 
different concentrations of statins, and looking at several aspects of osteoblast differentiation. 
The effect of various BMP2 delivery methods on osteogenesis was also investigated, and its 
effect on MSCs from different species was determined. Second, a tissue engineering approach 
for cartilage repair was attempted.  Chondrogenic differentiation of MSCs was investigated by 
introducing the transcription factor SOX9, and mechanical loading. The novel element of this 
investigation is the omission of exogenous growth factors in the medium, and the observed 
interaction of SOX9 and mechanical load. 
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Chapter 2 Methods
2.1 Cell culture 
All cell culture work should be carried out under sterile conditions, as described 
elsewhere.(Freshney, 2000) (Freshney, 2000) 
Table 2-1 Expansion media used for different cell types  
HeLa High-glucose DMEM, 10% FBS 
HEK293 High-glucose DMEM, 15% FBS 
COS7 High-glucose DMEM, 10% FBS 
MSC MEM, 10% FBS, 5 ng/ml basic fibroblast growth factor (bFGF) 
2.1.1 MSC isolation 
Bone marrow can be found in the hollow interior part of several bones in the human body. 
Most frequently used sources are iliac crest, sternum, and at the epiphyseal ends long bones 
(femur and humerus). MSCs are a heterogeneous population of non-hematopoietic cells of the 
bone marrow. They can be isolated from other cell types by Ficoll centrifugation, and 
subsequent attachment to plastic. Total bone marrow is diluted and layered on a Ficoll cushion. 
During centrifugation, erythrocytes and granulocytes (pellet) are separated from mononuclear 
cells (plasma-Ficoll interface). Mononuclear cells are plated on cell culture flasks, and 
incubated for 1 day. Non-adherent (mostly hematopoietic) cells are removed, and adherent, 
colony forming cells provide the MSC population. 
Materials 
 phosphate buffered saline (PBS) 
Ficoll, Histopaque-1077 (Sigma-Aldrich Chemie GmbH, Steinheim, Germany ) 
Methylene Blue by Löffler (Fluka 66725) 
DMEM (Invitrogen, Paisley, UK): Supplemented with 0.11 g/l Sodium pyruvate and 
3.7 g/l NaHCO3. Can be stored at 4°C for up to 3 weeks. 
FBS (Invitrogen, Paisley, UK, stored frozen in 30 ml aliquots, thawed and added to 
medium just before use) 
100 U/ml penicillin + 100 g/ml streptomycin (Invitrogen) 
Tissue culture flasks (TPP, Trasadingen, Switzerland) 
Sterile pipettes 
50 ml conical tubes (TPP) 
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Human bone marrow was obtained with ethical approval and the written consent of the patients 
undergoing hip replacement surgery. The marrow (30-60 ml) was aspirated into several 
heparin-containing (15’000 IU/8.5 ml) S-Monovettes (Sarstedt, Germany). The samples were 
kept at room temperature during shipping, and the MSCs were isolated within one day of 
harvesting. 
Procedure 
1) Dilute bone marrow aspirate with 4 ml of DMEM + 5% FBS per 1 ml of aspirate 
2) Spin down 5 min, 200 RCF, remove fat layer and supernatant, resuspend pellet in 
same amount of DMEM + 5% FBS. 
3) Put 17 ml of room temperature Ficoll in a 50 ml conical tube 
4) Pipette 33 ml aspirate gently on top of the Ficoll while tilting the tube as much as 
possible without spillage 
5) Centrifuge at 800 RCF for 20 min at room temperature (RT), at lowest 
acceleration/brake 
6) The mononucleated cells now form an interface that can be collected using a 
syringe or a pipette. To make sure that all cells are collected, also collect 1-2 mm 
above and below the interface. 
7) Add at least 3× volume of DMEM + 5% FBS to the collected interface, mix gently, 
centrifuge at 565 RCF for 10 min at RT. Remove sn. using the vacuum aspirator. 
8) Resuspend the cells in 10 ml of medium. 
9) Stain a small volume of cells with methylene blue (50+50 l, 10 min) 
10) Count the cell number using trypan blue (the nucleated cells are stained blue; count 
only the big and homogeneously stained cells, not the very small ones) 
11) Seed 4×106 cells per 75 cm2 in 15 ml DMEM + 10% FBS, leave at 37° 5% CO2, 
95% humidity for 1 day in order to let the cells attach. 
2.1.2 MSC culture 
Materials 
MEM (Invitrogen, Paisley, UK)  
FBS (Invitrogen)  
bFGF (Fitzgerald Industries International, Concord, MA, USA)  
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Tris-balanced salt solution (TBSS) w/o Ca, Mg (8.0 g NaCl, 1.0 g D-glucose-
monohydrate, 1.0 g NaHCO3, 0.2 g KCl, 0.05 g NaH2PO4. Add phenol-red, pH to 7.4 
with CO2, fill up to 1 l with deionized water.)  
1000x Ca, Mg (2.65 g CaCl2.2H2O, 2.14 g MgCl2.6H2O in 10 ml deionized water.)  
TBSS (TBSS w/o Ca, Mg + 1000× Ca, Mg solution)  
Trypsin-EDTA (ethylenediaminetetraacetic acid) (diluted in TBSS w/o from a 10× 
solution (Gibco, 15400-054))  
Collagenase type 2 (Worthington, LS004177, dissolved in TBSS, 70 U/ml)  
Culture medium ( MEM + 10 %FBS + 5 ng/ml bFGF 
Dimethylsulfoxide (DMSO) 
Procedure 
MSCs are fibroblastic cells in shape. They can be seeded at 1-2 million cells per 150 cm2 flask. 
Culture cells in MEM with 10% FBS. Addition of bFGF helps to maintain a multipotent 
phenotype, and increases proliferation.(Mastrogiacomo et al., 2001) If supplemented with 
bFGF, the cell population doubles approximately every 3 days. At confluence, 5 million cells 
can be harvested from a 150 cm2 flask. Bone marrow stromal cells (BMSCs) are only partially 
affected by contact inhibition, therefore they may become overconfluent. Always subculture 
them before they reach confluence (70-80%). Split them to a dilution of 4-8×. Cells can be 
passaged safely as many as 3-4 times without a loss in proliferation rate or differentiation 
capacity. 
When passaging cells, they are normally detached by trypsinization. But in some cases – 
especially when the monolayer becomes confluent – an abundant collagen matrix is produced, 
which can not be digested by trypsin. When this happens, the cells are detached from the flask, 
but still held together by the matrix. Thus, no single-cell suspension can be produced. To 
prevent this, a collagenase treatment is necessary before the trypsinization. 
1) Prepare a solution of collagenase type 2 in TBSS and filter it through a 22 μm filter. 
Prepare 10 ml per 150 cm2 flask.  
2) Wash cell layer with TBSS w/o Ca, Mg  
3) Add the Collagenase solution to the monolayers. Incubate for 30 min at 37°C.  
4) Prepare trypsin-EDTA solution. (10 ml per 150 cm2 flask)  
5) Prepare appropriate amount of culture medium.  
6) Wash cell layer with TBSS w/o Ca, Mg  
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7) Add trypsin-EDTA briefly, and then remove it, so that only a thin layer of trypsin 
remains on the monolayer. Incubate for 5-10 minutes at 37°C.  
8) Resuspend the detached cells in culture medium, and seed them at an appropriate 
concentration.  
Alternatively, resuspended MSCs can be stored in 90% FBS 10% DMSO. Aliquot and freeze 
as explained by Freshney (2000). They are not particularly sensitive to the cooling rate, 
although they should not be frozen very rapidly. Ideally, a cryo 1°C freezing container (“Mr. 
Frosty”, Nalgene) should be used, but placing them in 80°C in a plastic or paper box is also 
adequate. Transfer the BMSC to liquid N2 the next day. 
2.1.3 Differentiation conditions 
MSCs have been shown to be able to differentiate into several cell types. (Dennis et al., 2002) 
To prove the multi-potential of a cell population, three assays are carried out routinely: 
Osteogenic, adipogenic and chondrogenic. (Figure 2-1) 
 
Figure 2-1 MSC differentiation 
Illustration of MSC differentiation into three different mesenchymal lineages. A – Osteogenic (von Kossa 
staining); B – Chondrogenic (Safranin O-fast green); C – Adipogenic (Oil Red O) 
2.1.3.1 Osteogenic differentiation 
Seed cells at a density of 16,000 cells/ cm2 leave cells to attach overnight. Medium change 




100 nM dexamethasone 
50 μg/ml ascorbate-2-phosphate 
100× non-essential amino acids 
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10 mM -glycerophosphate 
Supportive evidence of osteogenic differentiation is acquired by alkaline phosphatase (ALP) 
activity measurement after 2 weeks (page 36), 45Ca incorporation (page 63) and von Kossa 
staining (page 56) to prove calcium deposition after 3 weeks. 
Statin study 
Non-induced control samples were treated with the medium described above, but omitting 
dexamethasone (basal medium). In the statin-treated samples this basal medium was 
supplemented with lova- and simvastatin at concentrations of 1 and 5 μM. 
2.1.3.2 Adipogenic differentiation 
Seed cells at a density of 16’000 cells/ cm2 leave cells to attach overnight. Medium change 




5 μg/ml insulin  
100 nM dexamethasone 
0.5 mM isobutylmethylxanthine  
60 μM indomethacin 
Adipogenic differentiation is confirmed by Oil Red O staining (page 55), and up-regulation of 
(adipocyte fatty acid binding protein 4 and peroxisome proliferator-activated receptor gamma) 
expression (Real-time RT-PCR, page 49). 
2.1.3.3 Chondrogenic differentiation 
Materials 
200’000 MSCs per pellet 
15 ml conical tubes 
Chondrogenic Medium: 
DMEM high glucose (with pyruvate, Invitrogen) 
Non-essential amino acids (100×, Invitrogen) 
ITS+1 (100×, Sigma) 
Ascorbate-2-phosphate sesquimagnesium salt (50 mg/l, 170 M, Sigma) 
Dexamethasone (100 nM) 
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Transforming growth factor beta 1 (TGF- 1) (10 ng/ml) 
Penicillin-Streptomycin (100×, optional, Invitrogen) 
Procedure 
1) Trypsinize progenitor cells and centrifuge at 565 RCF to form a pellet 
2) Resuspend pellet in chondrogenic media (0.5 ml per 200’000 cells) 
3) Transfer cell suspension to 15 ml centrifuge conical tubes 
4) Spin tubes at 400 RCF for 5 min to promote aggregate formation 
5) Loosen capsa and place in incubator for 21 days, changing media every 3-4 days 
Chondrogenic differentiation is proved by up-regulation of SOX9, aggrecan (ACAN) and 
collagen type II alpha 1 chain (COL2A1) expression (Real-time RT-PCR, page 49), and 
safranin-O staining (page 56).(Johnstone et al., 1998; Yoo et al., 1998) 
2.1.4 Cell culture in sponges 
2.1.4.4 Trypsinization and Seeding 
Materials 
Polyurethane (PU) sponges (90-300 m pore size, cylindrical d=8 mm, h=4 mm) 
MSCs 2×106 per scaffold 
TBSS w/o 
Sterile Eppendorf tube caps 
10% FBS DMEM 
6-well plates (TPP) 
Culture medium for scaffolds: 
DMEM high glucose (with pyruvate, Invitrogen) 
Non-essential amino acids (100×, Invitrogen) 
ITS+1 (100×, Sigma) 
Ascorbate-2-phosphate sesquimagnesium salt (50 mg/l, 170 M, Sigma) 
Penicillin-Streptomycin (100×, Invitrogen) 
-aminocaproic acid (EACA) (5 M) 
Preparation 
                                                 
a This is to allow gas exchange 
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1) Place the scaffolds and in a Petri dish with sterile tweezers, add enough medium to 
cover them, and gently press them, to remove most of the air from the pores, but not 
damage them.  
2) Cover the dish, and put it in the vacuum chamber, and start up the vacuum. Leave it in 
there for at least 1 hour. This removes more air from the pores. 
3) Prepare trypsin-EDTA (in TBSS w/o or PBS), DMEM 10% FBS, and enough TBSS 
w/o to wash the monolayers.   
4) Wash cell layers with TBSS w/o ( 20 ml per 300 cm2 flask) 
5) (optional: Digest monolayers with collagenase for 30 minutes at 37°C, then wash again 
with TBSS w/o to remove Ca2+)  
6) Add trypsin, spread it in the flask, and remove excess solution. Incubate for 5-10 
minutes at 37°C. 
7) Collect detached cells by washing with 10% FBS medium. Place them in a Falcon tube, 
and count with a haemocytometer.  
8) In experiments involving adenoviral transduction with a construct expressing GFP, 
plate 5×105 cells in a 25 cm2 flask. This is for determination of transduction efficiency 
by flow cytometry after 3 days.   
9) Thaw fibrinogen, thrombin and dilution buffers. Dilute fibrinogen 3× and thrombin 
500×.b Use 75 μl per scaffold from both.  
10) Centrifuge 2×106 cells per scaffold at 565 RCF for 7 minutes. Discard supernatant.  
11) Place the sterile Eppendorf caps in 6-well plates.  
12) Resuspend the cell pellet in an appropriate amount of fibrinogen. 
13) Remove medium from the soaked sponges with a 10 ml plastic pipette or with a Pasteur 
pipette connected to a vacuum pump. 
14) Pipet 75 l thrombin in each cap 
15) Pipet 75 l fibrinogen-cell mixture in the cap, and mix it with the thrombin by pipetting 
up and down until homogeneous. 
16) Squeeze the scaffold between the levers of the tweezers, and place in the cap. Release it 
slowly, so that it sucks up the cell-fibrinogen-thrombin suspension. If there is a lot of 
fluid around it, press down and release several times. Some bubbles may be formed.  
                                                 
b Without dilution, the viscous fibrinogen is not able to penetrate the smaller, inner pores of the sponges. Also, 
thinner gel enables better diffusion of nutrients. The dilution of thrombin is necessary to slow down the gelation 
process, which leaves enough time to deliver the mixture into the sponges. 
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17) Place them in the cell culture incubator for 1 hour, or until fibrin gel forms. 
18) In the meantime, prepare culture medium 
19) Remove sponges from the Eppendorf tube caps using tweezers, and place then in 6-well 
plates 
20) Add 5 ml culture medium per well in a 6-well plate 
21) Medium change is necessary 3 days later.c 
2.2 Loading 
After the last passage, MSCs were cultured in monolayer until ~90% confluency, and were 
transduced with either adenovirally introduced green fluorescent protein (AdGFP) or 
adenovirally introduced SOX9 (AdSOX9) (Lanthofection, page 33).d In the first two 
experiments a non-transduced group was also applied. The cells were trypsinized, and seeded 
onto fibrin-PU scaffolds (Trypsinization and Seeding, page 21) at 2×106 cells per scaffold 
(~107 ml 1). These were then cultured for 6 days in 6-well plates in 5 ml media per scaffold. 
The medium was changed once, on day 3. 
The scaffolds were then transferred into polyaryletheretherketone (PEEK) sample holders 
padded with a PU ring made from the same material as the scaffold (without fibrin). The 
loading period started on day 7. The three transduction groups were divided further into a 
loaded and non-loaded sub-group (Table 2-2). Only 3 ml of medium was added per scaffold, 
and this was changed every other day. 
 Non-transduced AdGFP AdSOX9
Non-Loaded NN GN SN 
Loaded NL GL SL 
Table 2-2 Experimental groups 
The table shows the 6 treatment groups and their two-letter codes for later use 
During loading, a commercially available ceramic hip ball (32 mm in diameter) was pressed 
onto the cell-seeded scaffold (Figure 2-2). Interface motion was generated by oscillation of the 
ball about an axis perpendicular to the scaffold axis. Superimposed compressive strain was 
applied along the cylindrical axis of the scaffold. In the first 8 days (day 7-14) the constructs 
                                                 
c At this time, transfer the sponges into new 6-well plates, because loosely attached cells form a monolayer in the 
bottom of the well, and may affect cell differentiation within the scaffolds. 
d After transduction, the cells were confluent. During MSC expansion, it is important to keep the cells dividing, 
hence they were subcultured at 70-80% confluency; while before seeding on the scaffolds, high cell numbers are 
preferred. 
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were exposed to ball oscillation of ±25° at 1 Hz with 10% static offset strain for 1 hour per 
day. In the following 6 days additional dynamic compression was applied at 1 Hz with 10% 
sinusoidal strain, superimposed on the 10% static offset strain, resulting in strain offsets 
ranging between 10-20%.(Grad et al., 2005; Wimmer et al., 2004) 
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Figure 2-2 Loading bioreactor 
Left: A schematic 3D representation of a load cell in the bioreactor. The scaffold is a white cylinder in the middle 
of the PEEK holder (1). It is surrounded by a PU ring, which is placed in the space between the scaffold and the 
holder (2, it is left empty for better visibility). A ceramic hip ball (3) is used for stimulation, which is able to rotate 
around the suspension axis (4), and move up and down along the Y axis of the picture (green arrow in lower left 
corner). 
Right: A photograph of the bioreactor setup before loading. 
Transduction













Figure 2-3 Experiment timeline 
2.3 Gene transfer 
2.3.1 Transfection 
2.3.1.5  VLP 
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Materials 
10× Dissociation buffer pH7.5 (autoclaved): 
o 100 mM Tris  
o 100 mM ethylene glycol tetraacetic acid (EGTA) 
o 1.5 M NaCl 
Bovine serum albumin (BSA) 
Virus-like particles (VLP, prepared fresh, or stored at 20°C aliquotted) 
Dithiothreitol (DTT, 250 mM, ~1 ml) 
Dialysis bags 
Eppendorf caps with a hole in the cap 
10× Reassociation buffer pH7.5, optionally autoclaved 
o 100 mM Tris 
o 10 mM CaCl2 
o 1.5 M NaCl 
DNA (5 g/well) 
PEI-transferrin (Polyethylenimine-transferrinfection Kit, Bender MedSystems, 
BMS1004/BMS1004) 
Procedure 
1) Prepare cells (10’000 cells/well in 24-well plate, attach overnight) 
2) Measure VLP concentration using Bradford assay. Use BSA as standard. 
3) VLP dissociation (100 l final volume per well) 
5 g VLP (x l) 
10 l 10× Dissociation buffer 
2 l 250 mM DTT (5 mM final concentration) 
100-x-y l deionized water 
4) Vortex, then incubate at RT for 1 h.e 
5) Add 0.5 g DNA to the mixture (in y μl|y<10) 
6) Prepare an Eppendorf tube with a hole in the cap (to hold the dialysis tubing) 
7) Fill the DNA (or RNA)-VLP mixture in the tube, and clamp it with the Eppendorf.f 
8) Fill the hole with re-association buffer (so that no air gets trapped there). 
9) Dialyze in reassociation buffer overnight at 4°C 
                                                 
e This is necessary to dissociate VLPs as much as possible 
f The volume of the sample will increase during dialysis 
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10) The assembled particles are mixed with PEI-transferrin with the PEI:VLP ratio 1:10. 
Vortex, incubate at RT for 30 min. 
11) The appropriate mixture added to the cells in a 24-well plate dropwise. The cells are 
exposed to the transduction reagents for 1-2 days, until assayed. 
2.3.1.6 Electroporation 
Materials 
Nucleofector solution (0.5 ml supplement + 2.25 ml Nucleofector solution, stable for 3 
months at 4°C) 
DNA (plasmid dissolved in Tris-EDTA (TE) buffer at 1-5 μg/ml) 
500 μl pre-warmed medium per sample 
medium: DMEM + 20% FBS 
Protocol 
Seed at least 400’000 cells per 150 cm2 flask 
Passage cells at 70-80% confluency 
Passage cells 6-7 days before electroporation, and let them expand to max. 90% confluency for 
better resultg 
12) Dilute 2 μg DNA per 500’000 cells to max 5 μl 
13) Pre-warm Nucleofector Solution to RT 
14) Pre-warm medium to 37°C 
15) Prepare 6-well plates with medium  
16) Wash cell once with TBSS (or PBS) 
17) Trypsinize (or, if confluent, collagenase-trypsinize) cells 
18) Remove cells from the flask with TBSS + Ca, Mg 
19) Centrifuge 200 RCF 10 min 
20) Resuspend cells in TBSS 
21) Count viable cells 
22) Centrifuge 500’000 cells per reaction in separate tubes (200 RCF 10 min) 
Transfection 
Carry out the following for each sample separately: 
                                                 
g Transfection is more efficient when the cells are divinding. Hence it is important not to let them reach 
confluency. This applies to all transfection methods, not only nucleofection. 
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23) Resuspend each pellet with 100 μl supplemented nucleofector solution just before 
transfection 
24) Mix gently with 2 μg DNA 
25) Transfer all into a cuvette (should cover the bottom, no bubbles!) 
26) Close with a blue cap 
27) Insert cuvette in the holder, and rotate clockwise to the final position 
28) Select program (U23 or G22) 
29) Press X 
30) Repeat this for all samples 
Recovery 
31) Remove cuvette immediately after transfection  
32) Add 500 μl warm medium (20% FBS), remove from the cuvette slowly, because shear-
forces may damage the cells while pipetting. Place the cell suspension in the prepared 
6-well plates. 
33) Assess cell viability by the number of attached cells after 2 hours 
34) Detect gene expression after 24 hours 
2.3.2 Transduction (Lanthofection) 
2.3.2.7 Virus propagation 
Adenovirus vectors do not contain certain essential genes (E1, E3) for virus replication, 
therefore they infect, but do not propagate in normal eukaryotic cells. To amplify these vectors, 
a specially constructed cell line, Human embryonic kidney #293 (HEK293), is necessary, 
which complement for the missing genes. 
70% confluent 293 monolayer 
Virus stock or infectious cell lysate 
DMEM, FBS 
Cell culture flask (TPP) 
15 and 50 ml polypropylene tubes 
12 ml ultracentrifuge tubes 
Ultracentrifuge with swinging bucket rotor 
500 ml 10 mM Tris-HCl pH 7.9 
o 606 mg Trisma base 
o add ~400 ml DW 
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o Set pH to 7.9 with 6M HCl (careful!) 
o dilute to 500 ml 
Cesium-chloride solutions 
o 1.4 g/ml: 53.0 g CsCl + 87 ml 10 mM Tris-HCL pH 7.9 (fine-tune it afterwards) 
sterile filter (0.22 um) 
o 1.2 g/ml: 26.8 g CsCl + 92 ml 10 mM Tris-HCL pH 7.9 (fine-tune it afterwards) 
sterile filter (0.22 um) 
o also sterile filter the 10 mM Tris-HCL 
0.5 M EDTA (50 ml): 
o weigh 7.3 g EDTA in 30 ml DW 
o add solid NaOH grains until it is dissolved (stir continuously) 
o set pH to 8.0 
1 M Tris-HCl pH 7.5 (100 ml) 
o 12.11 g Trizma base 
o add ~65 ml DW 
o set pH to 7.5 with 6M HCl (~25 ml) 
o dilute to 100 ml 
PBS (1 liter): 
o 8 g  NaCl 
o 0.2 g  KCL 
o 1.42 g  Na2HPO4.2H2O 
o 0.20 g KH2PO4 
o Dissolve them in 900 ml DW 
o set pH 7.2 
o fill it up to 1 liter 
o sterilize using a 0.22 um filter 
Dialysis buffer (3×0.5=1.5 liter): 
o 15 ml 1M Tris pH 7.5 (-> 10 mM) 
o 60 ml 5M NaCl (-> 200 mM) 
o 3 ml 0.5 M EDTA (-> 1mM) 
o 60 g sucrose (-> 4 %w/v) 
o finally, add 1422 ml H2O 
1) Prepare 70% confluent monolayer of HEK293 cells 
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2) Add ~5 μl virus stock or infectious cell lysate into 5-10 ml DMEM solution and add it 
to 150 cm2 monolayerh 
3) Incubate for about 1 hour, and add up to 30 ml DMEM 10% FBS 
The virus starts to replicate in the infected cells. The sign of adequate cytopathic effect is that 
most of the cells round up, and start to detach from the flask. If the cells are left too long, they 
start to burst because of saturation by virus particles. Ideally, cells should be harvested just 
before this point, because they can be concentrated by centrifuging the cells. After the virus is 
released in the medium, they can not be concentrated anymore. 
4) Harvest the cells by tapping the flask, and collect all medium into 50 ml polypropylene 
tube 
5) Centrifuge at 565 RCF for at 4°C 10 min to pellet cells containing viruses 
6) Discard sn., resuspend in TE buffer (~3 ml per 300 cm2) 
7) Freeze-thaw 3× alternating between liquid N2 and 37°C waterbath. 
8) Add 50 U/ml benzonase (not more) to the cell pellet, and incubate at 37°C for 30 min 
(no longer!) 
9) Centrifuge at 2000 RCF, 4°C for 10 min to pellet cell debris and genomic DNA. 
Aspirate and keep supernatant on ice. 
10) Prepare CsCl density gradient just before centrifuging to minimize mixing of the layers 
(Figure 2-4). Add 1.2 g/ml solution first, then slowly add 1.4 g/ml to the bottom with a 
syringe and needle. Gently layer the lysate on top using a 10 ml plastic pipet. 
11) Centrifuge under vacuum at 4°C, 40’000 RCF for 1 h. No acceleration/deceleration 
recommended, because it can stir up the gradient. 
                                                 
h The solution should cover the cell layer, but try to keep the volume to the minimum, in order to increase 
efficiency 
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Figure 2-4 CsCl gradient centrifugation 
12) Harvest the lower viral band using a 16-gauge needle and a 3 ml syringe. Don’t harvest 
more than 1.5 ml, but try to remove the band completely. The more concentrated, the 
better. Normally, it is possible to aspirate the band in ~0.5 ml volume. 
13) Repeat steps 10-12 two more times 
14) Transfer last aspirate into dialysis bags and dialyze in 500 ml pre-chilled dialysis buffer 
for 6 hours. Repeat two more times. 
15) Approximate concentration can be determined by measuring the optical density at 
260 nm (OD260). 1 OD value corresponds to 1012 viral particles per ml. Aliquot the 
dialyzed solution before freezing down at 80°C, because repeated freeze-thaw cycles 
decrease the transduction efficiency of the virus. 
The proportion of infectious virus particles usually falls between 1-10%. More accurate 
determination can be achieved using a plaque assay.  
2.3.2.8 Plaque assay 
The plaque assay is based on the fact that viruses are diluted adequately so that only a few 
infectious particles are deployed on a carpet of cells, and covered by an agarose gel. When the 
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single infected cells lyse, the spreading virus particles are localized by the gel, and result in the 
development of opaque areas in the cell culture dish, called plaques. These can be counted, and 




TBSS (containing Ca++ and Mg++, sterile) 
2× DMEM (sterile filtered) 
2% agarose (in DW, freshly prepared and sterilized) 
FBS (sterile) 
Procedure 
Thaw a vial of 293 cells, and scale them up in tissue culture flasks as necessary. The area of a 6 
cm dish is ~28 cm2. When splitting cells from flasks to 6 cm dishes, the cells should be 50% 
confluent in the flask. Subculture them so that the cell density is about half in the dishes. (eg. 6 
dishes from a 75 cm2 flask) This is to ensure that the next day the cell layers are ~50% 
confluent. That is when the transduction should be done. When seeding the cells in 6 cm 
dishes, pipet the cell suspension in the dish, cover, and do not touch it. Leave it for 20 min in 
the sterile hood (let the cells attach to the plastic), and transfer them into the cell culture 
incubator very carefully. Any kind of agitation will cause the unattached cells to accumulate in 
the middle of the dish, and the cell layer will be uneven. 
5 ml overlay is needed per dish. It is prepared by mixing 2× DMEM and agarose 1:1. Weigh 
2% agarose and add appropriate amount of distilled water (or deionized water) in a sterile 
bottle. Autoclave. 
Prepare dilutions of the adenovirus in TBSS on ice. The virus should not be under- or over-
diluted. In order to be in the right range, an 8-step dilution series is prepared, where each step 
is 10× diluted. Generally, one can start by 100× or 1000×, and then down 10 by 10. For each 
dish (each dilution) 1 ml virus solution is needed. 
Wash cells once with TBSS. Add it carefully, because the cell layer is very loosely attached, it 
can be blown away by the stream. Soak it for half minute, then remove the wash solution. 
Add the virus dilutions to the respective dishes drop by drop. Again, very carefully, so that the 
cell layer stays intact. 
Incubate for 60 minutes at 37°C in a humidified incubator. 
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Take out the agarose from the autoclave, and place it in the 37.5°C waterbath, together with the 
FBS and 2×DMEM. 
After the incubation time is over, and after the agarose has cooled down, overlay by mixing 1:1 
2×DMEM:agarose, and add 2% FBS to it. Remove the virus solution from the dishes, and add 
the overlay dropwise. It is very viscous, so the cell layer can be damaged easily. 
Place the dishes to 4°C for 20-30 minutes, until the overlay is hardened. Keep them at 37°C in 
a humidified incubator during the observation period. 
Observation should be performed at least daily. After 3-6 days they undergo virus-induced cell 
lysis, and infect their neighbors. When those cells also lyse, the resulting plaques can be 
observed macroscopically as round clearings on the opaque cell layer (plaques). This can be 
best observed by holding the dishes towards a light source, and tilting it. The first plaques 
usually appear 4-7 days after transduction. If the viruses contain GFP, the development of 
plaques can be followed by fluorescence microscopy. 
2.3.2.9 Lanthofection 
This procedure is a simple adenoviral transduction procedure, enhanced by addition of LaCl3. 
There are a number of possible explanations why this enhances transduction efficiency.(Palmer
et al., 2008) It is certainly connected with the lanthanum’s ability to form a fine precipitate 
with the anions (mainly phosphate) of the culture medium. Because of its triple positive charge, 
it also masks the negative charges of the cell membrane and viral capsid (or DNA), thereby 
antagonizing repulsive forces. However, it was postulated, that most likely, La3+ is able to 
somehow circumvent the normal coxsackie-adenovirus receptor (CAR) -related pathway of 
adenovirus uptake, possibly enabling defective (misassembled) virus particles to take part in 
the infection process. Thereby lanthanum not only enhances transduction rates, but also 
transgene expression per cell.(Palmer et al., 2008) 
Materials 
DMEM, FBS 
300 cm2 cell culture flask (TPP) 
80% confluent MSCs 
Adenoviral stock (AdGFP or AdSOX9) 
10 mM LaCl3 stock 
50 ml polypropylene tube 
Procedure 
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8xT300 flasks of MSCs (~80% confluent) 
AdGFP virus, AdSOX9 virus (100× multiplicity of infection, i.e. 100 MOI) 
Virus preparation for one 300 cm2 flask (5-10 million cells): 
1) Mix 8 ml DMEM with 100 MOI virus 
2) Add 80 l 10 mM LaCl3 dropwise (100 μM final concentration) 
3) Mix well (invert tube several times or vortex gently) 
4) Mix repeatedly at least twice during the 30 min incubation at RT 
5) Meanwhile prepare and change medium on the cells (20 ml DMEM 10% FBS and Pen-
Strep) 
6) After incubation, add 8 ml virus solution per flask. Add it dropwise with a 10 ml plastic 
pipet, and spread it evenly over the whole surface. Incubate overnight (O/N) at 37°C. 
2.4 Cell viability 
2.4.1 MTT assay 
The assay is based on the activity of a mitochondrial reductase, which is able to convert a 
tetrazolium salt into a formazan product. The formazan absorbs at a characteristic wavelength, 
which can be read on a standard enzyme-linked immunosorbent assay (ELISA) plate reader. 
Absorbance is directly proportional to the number of living cells in culture in most systems. 
Therefore it can be used to determine cytotoxicity of certain compounds, or as a non-
radioactive alternative to tritiated thymidine-based cell proliferation assays. 
Materials 
Medium without phenol red (DMEM/F12, Sigma D2906) 
5 mg/ml Thiazolyl Blue Tetrazolium Bromide (MTT) 10× stock (Sigma M2128) 
MSCs in 24-well plates (20’000 cells per well = 11’000 cells/cm2) 
PBS 
Procedure 
1) MSCs are seeded in 24-well plates at a density of 11’000 cells/cm2, and let to attach 
overnight 
2) Culture media of interest are added the next day 
3) At each time-point (day 0, 4, 11, 14 and 18) remove media and the wash cell layers 
with PBS. 
4) Add 0.5 ml DMEM/F12 and 50 l 5 mg/ml MTT to each well 
5) Incubate at 37°C, 95% humidity for 4 hrs 
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6) Dissolve formazan salt by the addition of 0.5 ml 2-propanol per well, cover with 
aluminum foil and shake on an orbital shaker (SM25, Edmund Bühler, Tübingen, 
Germany) at RT, 150 cycles/min, for 1 h. 
7) Read absorbance at 570 nm on an ELISA plate reader. In these experiments it was read 
at 550 nm because of the lack of 570 nm filter. 
2.4.2 Proteinase-K digestion 
Proteinase-K is a broad-specificity serine protease, which cleaves adjacent to aromatic and 
aliphatic amino acids. It works in a wide pH range (4-12). Proteinase-K can be used during 
DNA isolation to inactivate DNases, or to dissolve protein-rich matrix. 
Material 
PBE (phosphate buffered EDTA) 
o 10.68 g/l NaH2PO4.2H2O 
o 8.45 g/l Na2HPO4.7H2O 
o 3.36 g/l Na2EDTA 
o Dissolved in Milli-Q water, pH is adjusted to 6.5 
0.5 mg/ml Proteinase K in PBE, Roche #1000144 
Procedure 
If the sample is large, it should be cut into smaller (~2-4 mm) pieces in order to facilitate the 
digestion process. Drop the samples into prepared Eppendorf tubes, and immediately pipet at 
least 5× volume of proteinase-K solution on top. Make sure it covers the sample. Close tubes 
and incubate overnight at 56 °C. Remove the samples the next day, squeeze if necessary. The 
samples can be stored at 20°C. If the solution is cloudy before use for an assay, vortex and 
centrifuge it at 5000 RCF for 5 min, and use the clear supernatant. 
2.4.3 DNA amount 
Diploid cells contain 2 copies of their specific genomes, therefore the amount of DNA 
contained in their pure cultures can be used as an indicator of cell number. In turn, this is useful 
to normalize biochemical markers or determine growth-curves. DNA absorbs light at around 
260 nm, but this interferes with RNA and other substances, hence a more specific method is 
necessary. This method is based on the enhancement of fluorescence seen when bisbenzimide 
(Hoechst 33258) binds to the minor groove of DNA. Crude homogenates in which chromatin 
has been dissociated with high salt buffer can be assayed directly and reliable in a few minutes. 
The dissociation of chromatin is critical to accurate determination of DNA in biological 
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materials. The fluorescence of Hoechst 33258 is related to the AT content of a DNA sample, so 
it is very important to use a standard similar to the sample under investigation. The calf thymus 
DNA standard is double-stranded, highly polymerized, and it has an approximate content of 
60% AT (40% GC). (Labarca and Paigen, 1980) 
Materials 
PE HTS 7000 Bio Assay Reader  
96 well white plates 
Phosphate buffered saline, pH7.4 containing 2 M NaCl (DPBS) 
o 25 mM KH2PO4 (3.402 g) 
o 25 mM Na2HPO4 (3.55 g) 
o 2.0 M NaCl (116.88 g)  
o 800 ml distilled water 
o pH 7.4 adjust pH with 5 N NaOH, ca. 4.5 ml 
o fill up to 1000 ml 
100 μg/ml DNA standard (in DPBS): Calf Thymus DNA Sigma ‘ultra pure’, #D4764 
Proteinase-K extracted samples (as described on page 35) 
1 mg/ml Hoechst 33258; Store in the dark, Hoechst is light sensitive  
Assay solution: Dilute Hoechst stock solution 2000× in DPBS 
Procedure 
1) Prepare DNA standard curve in PBE: 50 μg/ml, serially diluted 2×, down to 781.25 
ng/ml). The blanks consist of PBE. 
2) Pipet 40 l of standards / samples into 96 well white plates. Run samples in duplicates 
or triplicates. 
3) Add to each well 160 l assay solution. 
4) Tap the plate gently and read fluorescence emission at 465 nm with 360 nm excitation. 
This step must be done within 10 minutes. 
5) Prepare a linear standard curve E (465 nm) vs. DNA amount (ng/well) and calculate 
samples according to their fluorescence values. 
2.5 Biochemical analysis 
2.5.1 ALP activity 
This assay depends on the hydrolysis of p-nitrophenyl phosphate by phosphatase enzymes 
active at alkaline pH, yielding p-nitrophenol and inorganic phosphate. In alkaline solution, p-
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nitrophenol is converted to a yellow complex readily measured at 400-420 nm. The intensity of 
color formed is proportional to phosphatase activity. (Alini et al., 1994) 
Material 
Phosphatase substrate: 4-Nitrophenyl phosphate disodium salt hexahydrate (Sigma, #N-
2765, 20 mg tablets) 
Standard Solution: p-Nitrophenol (Sigma, #104-1, 10 mM stock) 
Alkaline Buffer Solution: 2-Amino-2-methylpropanol (Sigma, #A-9199, Syrup) 
Diethanolamine (Sigma, #D-0681) 
MgCl2 (Fluka, #63064) 
Glass reaction tubes 
96-well plate, flat bottom- Falcon, No: 3072 
0.1 M NaOH 
Tris-Triton-X (0.1% Triton-X in 10 mM Tris-HCl, pH 7.4) 
Procedure 
Preparation of samples 
1) Wash monolayers with PBS 
2) Extract cell layers with 0.1% Triton-X in 10 mM Tris-HCl, pH7.4 for at least 3 hours at 
4-8°C on a gyratory shaker. 
ALP quantification 
3) Prepare stock substrate solution: Dissolve five 20 mg tablets in 3.8 ml of 1 M 
Diethanolamine (pH9.8) containing 0.5 mM MgCl2. Can be stored at 20°C for 
6 weeks. Cover with aluminum foil to prevent damage from light! 
4) Prepare p-nitrophenol standard solution: Dilute stock solution (10 mM) 25× with Tris-
Triton-X (to 400 μM). Prepare fresh every time. 
5) Alkaline Buffer: Dilute the stock 7.6× with H2O. Store at 4°-8C.   
6) Prepare standard curve by mixing the following volumes as shown in Table 2-3. 
Reaction 
Add the following reagents to a glass tube (in this order): 
o 250 l Alkaline buffer 
o 100 l H2O 
o 50 l substrate solution 
o 100 l unknown sample (prepare one tube with Tris-Triton-X as reaction blank) 
7) Immediately vortex and incubate at 37°C in a heating block. 
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8) After exactly 15 min, remove from 37°C and stop the reaction by adding 0.5 ml of 
0.1 M NaOH 
9) Optionally dilute samples with too high values. Use the following mixture to dilute 
samples that are out of range (check color by eye). 
100 l Tris-Triton-X, instead of sample
250 l Alkaline Buffer 
100 l H2O 
50 l H2O (instead of substrate) 
500 l 0.1 M NaOH 
10) Measure absorbance at 405 nm. 











0.1 M NaOH 
[ l] 
0 0 100 250 150 500 
10 25 75 250 150 500 
20 50 50 250 150 500 
30 75 25 250 150 500 
40 100 0 250 150 500 
 
2.5.2 Ca-45 incorporation 
The rate of bone matrix deposition can be detected by 45Ca incorporation. (Alini et al., 1994) 
The rules of working with radioactive materials should be followed throughout this procedure. 
Should be performed only by trained personnel. 
Materials 
45Ca (Calcium chloride in aqueous solution) 
DMEM 
Formic acid (70%, Fluka Chemie AG) 
Scintillation bottles  (6.5 ml, Semadeni AG) 
Scintillation liquid (OptiPhase ‘Hi Safe’), MBV AG Analytische Systeme 
WinSpectral, Liquid Scintillation Counter, PerkinElmer 
Procedure 
1) Prepare labeling medium: 1.25 μCi/ml 45Ca in DMEM 10% FBS 
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2) Add 1 ml medium per well in a 24-well plate and incubate cells for 16 h at 37°C, 95% 
humidity 
3) Wash 3× with DMEM or PBS (soak it for 5 min each time) 
4) Samples can be frozen at 20°C at this stage for later analysis. 
5) Dissolve mineralized matrix with 70% formic acid. Use excess amount to cover the 
bottom of the dish, because some evaporation may occur later. 
6) Incubate at 65°C 60 min. Wrap the plate/dish in parafilm to reduce evaporation of 
formic acid. 
7) After the liquid has cooled down, pipet 0.5 ml into a scintillation tube, and dispense 
3.5 ml scintillation fluid into the tube. Vortex, and measure activity in a liquid 
scintillation counter. 
2.5.3 GAG quantification with DMMB 
Dimethylmethyleneblue (DMMB) is a strongly metachromatic dye for histochemical detection 
of sulfated glycosaminoglycans. A sensitive and reproducible form of the analytical method 
was developed for the analysis of cartilage culture media (Farndale et al., 1986), and for 
assaying chromatographic column fractions for glycosaminoglycans and proteoglycans. In case 
of PU-fibrin scaffolds, glycosaminoglycans (GAGs) are extracted by proteinase-K (PK) 
digestion of the samples (page 35). 
Material 
PE HTS 7000 Bio Assay Reader. Filter 535 nm 
96 well assay plates (Costar # 3590) 
Chondroitin sulfate stock solution (1 mg/ml, chondroitin 4-sulfate sodium salt from 
bovine trachea, mixture of isomers, Fluka BioChemika, #27042) in distilled H2O. Store 
aliquots at 20°C. 
DMMB color reagent 
o 3.04 g glycine 
o 2.37 g NaCl 
o Dissolve in 0.8 l distilled water 
o Add 16 mg DMMB (1,9-Dimethyl-methylene blue, Aldrich cat. # 34,108-8) 
powder and stir over night at room temperature. Protect from light. 
o Adjust to pH 3.0 with 1 M HCl to give an absorbance of 0.31 at 525 nm. The 
reagent is stable in a brown bottle at room temperature for at least 3 months. It 
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is not recommended to store the color reagent at 4°C because its color fades 
reversibly, probably due to aggregation of dye molecules. Do not use if 
precipitation occurs. 
Procedure 
8) Sample preparation: scaffold samples are extracted by PK digestion overnight (page 
35). Media samples are thawed before measurement. 2×50 μl of each media sample and 
2×20 μl of PK extracts can be used. 
9) Standard preparation: Prepare standards: Dilute stock solution in culture medium for 
media samples and PBE buffer for PK extracts. Highest standard concentrations are 
40 μg/ml for the PK extracts and 16 μg/ml for media samples. Make a 7-member 2× 
dilution series in duplicates. Medium and PBE is used as blank. 
10) Pipet 20 or 50 μl standards / samples into the wells of a 96 well assay plate. Samples 
are measured in duplicates or triplicates 
11) Add 200 l DMMB color reagent to each well using a multiwell pipet 
12) Tap plate gently to mix solutions and read the absorbance at 535 nm and at 595 nm 
within 10 minutes. 
13) Prepare a linear standard curve A535/A595 vs. GAG concentration. 
2.5.4 35S incorporation 
Negative charges on large proteoglycans are a result of high degree of sulfation. Therefore, 
their synthetic rate can be determined by the incorporation of radiolabeled sulfur. The work 
should be carried out by trained personnel, following the radioactive safety guidelines. 
Materials 
Appropriate cell culture medium 
35S stock (Na2SO4 in aqueous solution) 
PK (page 35) 
Equipment for scintillation measurement (tubes, fluid, counter) 
Tweezers 
Eluent solution (example, ideally the same buffer as the sample) 
PD-10 columns (Amersham 17-0851-01) Vtotal=8.5 ml (d = 14.7, h = 50) 
Procedure 
1) Prepare culture medium containing with 2.5 μCi/ml 35S and pipet 1 ml per well on a 24-
well plate 
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2) Place scaffolds in the labeling medium, and incubate for 24 hours (in case of more 
active cells this time can be reduced) 
3) Remove scaffolds from the medium, and place them in an empty 24-well, plate, in 
which PK digestion can be (page 35). Cut the sponges into 3-4 smaller pieces with a 
scalpel, so that the digestion solution has a better access to the inside of the samples. 
4) Collect medium and transfer PK digests into Eppendorf tubes. 
Chromatography 
5) First clean the external parts of the column (remove salt deposits). 
6) Remove the top cap, then the bottom cap 
7) Wash PD-10 Columns with a total of ~25 ml eluent solution.  
8) When all the equilibration buffer has run into the column, apply the sample carefully on 
top of the gel bed. 
9) Collect fractions according to following scheme: 
10) Fraction 0. 600 μl of sample (radioactive!), when run into the column + 1900 μl of 
eluent solution. (total volume should be V0=2.5 ml) 
11) Fractions I-VII. 7×500 μl of eluent solution 
12) Discard fraction 0, keep the other fractions. 
13) Wash columns with a total of ~25 ml eluent solution. Attention: Collect this wash step 
as it elutes free isotope! 
14) Continue with next sample (step 8) or if finished, fill the column with storage solution 
(PBS+NaN3) and place cap on both top and bottom (in that order). 
15) Add 3.5 ml scintillation fluid to each vial and close with cap. Clean vial with a moist 
tissue paper. Vortex thoroughly. 
16) Measure radioactivity in a scintillation counter. The first 4 fractions will contribute to a 
peak consisting of high molecular weight molecules (incorporated 35S). The rest of the 
elution contains lower molecular weight compounds (practically free 35SO42-). 
2.5.5 OHP quantification 
Hydroxyproline (OHP) is a natural amino acid produced through post-translational 
modification of proline. It occurs almost exclusively in collagens, thus it can be used to 
determine the amount of connective tissue. First, proteins are hydrolyzed, which is followed by 
oxidation of the hydroxyproline to pyrrole, and quantification by color reaction and absorption 
measurement.(Edwards and O'Brien, 1980; Neuman and Logan, 1950; Stegemann and Stalder, 
1967; Woessner, 1961) 
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Materials 
PK digests of scaffold samples (page 35) 
12 M HCl 
Glass reaction tubes (can stand high temperature) 
Eppendorf tubes 
Vacuum exicator with NaOH trap (Speed-vac) 
96-well plate (Costar 3590) with adhesive plastic cover. 
Thermostat (65°C capable) 
Citrate-acetate buffer (250 ml) 
o 11.43 g Citric acid puriss. p.a., anhydrous (Fluka 27488, 238 mM) 
o 18 g Sodium Acetate (anhydr) (Fluka 71183, 878 mM) 
o 8.5 g Sodium Hydroxide (Fluka 71692, 850 mM) 
o 3 ml Acetic Acid (Fluka 45731, 210 mM) 
o Fill up to 250 ml deionized Water 
Chloramin-T solution (40 ml) 
o 564 mg Chloramine-T powder (R-de Haën 31224, 0.05 M) 
o 12 ml 2-methoxyethanol (Fluka 64719) 
o 20 ml citrate-acetate buffer 
o 8 ml DW 
4-dimethylamino butyric acid (DABA) solution (40 ml) 
o 4.5 g 4-dimethylamino benzaldehyde (Fluka 39070) 
o 7 ml perchloric acid (Fluka 244252) 
o 20 ml 1-propanol (Sigma 402893) 
o 13 ml DW 
OHP stock solution (1 mg/ml in DW) 
Procedure 
1) Use appropriate amount of PK digest for hydrolysis. 20-200 μl should be adequate. Fill 
up to 250 μl with distilled water 
2) Add 250 μl 12 M HCl, hydrolyze overnight at 110°C caps should be tight. If the 
solution evaporates, it can be reconstituted in distilled water. No 
lyophilize/neutralization is necessary in this case. 
3) Transfer samples into Eppendorf tubes and lyophilize under vacuum (Speedvac) as long 
as necessary. Interspersed NaOH trap is necessary to protect vacuum pump. 
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4) Reconstitute one or few samples in 250 μl distilled water. Check pH with a paper strip. 
If pH is 7±0.5, the solution can be considered neutral. Otherwise, dissolve the rest of 
the samples in citrate-acetate buffer.i 
5) Prepare standard curve ranging from20 μg/ml to 0.02 μg/ml. Dilute in the same 
solution as the samples are dissolved in. Also use this as blank. 
6) Pipet 112 μl/well of standards and samples on a 96-well plate in duplicates or 
triplicates. 
7) Prepare Chloramine-T and DABA solutions. 
8) Add 56 μl Chloramine-T solution to each well using a multiwell pipet. Cover plate 
tightly with an adhesive cover and incubate at RT for 20 minutes. 
9) Remove cover and add 84 μl DABA solution per well. Tap gently to mix. Milky 
precipitate may form, but this does not affect the measurement. Cover plate tight. 
Incubate at 65°C for 15 minutes. The color of the solution turns from yellow to bright 
red. 
10) Remove plate from thermostat, and remove strip. After the plate has cooled down, 
measure absorbance at 550 nm. Use linear standard curve to calculate concentrations. 
2.6 Molecular biology 
2.6.1 Western blot 
Size of SOX9 is: 56137 Da (hemagglutinin tag adds about 1000 Da) 
Recommended resolving gel concentration: 10% 
Materials 
                                                 
i OHP will be oxidized to pyrrole in the following reaction. This is inhibited by very acidic or alkaline samples. 
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Lysis buffer (20 ml) 
o 48 mg TrisHCl (20 mM) (buffer) 
o 0.6 ml 5 M NaCl (150 mM) (ionic strength) 
o 80 μl 0.5 M EDTA (2 mM) (chelates cations) 
o 0.2 ml Triton-X (1%) (detergent) 
o Set pH to 8.0 
proteinase inhibitors 
o 5 μg/ml pepstatin-A 
o 5 μg/ml leupeptin 
o 5 μg/ml aprotinin 
o 1 mM phenylmethylsulphonyl fluoride (PMSF) 
Proteinase inhibitor stock solutions (store at 20°C): 
o pepstatin-A: 1 mg/ml in methanol (200×) 
o leupeptin: 10 mg/ml in water (2000×) 
o aprotinin: 10 mg/ml in water (2000×) 
o PMSF: 100 mM in isopropanol (100×) 
2× Sample buffer 
o 130 mM Tris-Cl, pH8.0  
o 20% (v/v) Glycerol  
o 4.6% (w/v) sodium-dodecil sulfate (SDS) 
o 0.02% Bromophenol blue  
o 2% DTT 
Procedure 
2.6.1.10Cell Lysis 
1) Detach cells (tapping or trypsinizing, depending on the cell type) 
2) Pellet cells at 656 g, RT; and resuspend in ice cold lysis buffer. Use 20 μl per 500’000 
cells. 
3) Keep on ice for 30 minutes, mix a few times 
4) Determine protein concentration (Bradford assay) 
5) Mix appropriate amount in 2× sample buffer 
6) Boil 5 min, then cool at RT 5 min 
7) Briefly spin down samples and load on the gel 




Bio-Rad Mini Protean Gel 
electrophoresis system 
SDS-stock (10% w/v) 
Lower gel buffer stock (4×, 100 
ml): 
o 18.165 g Tris (1,5M) 
o 4 ml SDS stock (0.4%) 
o 80 ml DW 
o set pH to 8.8 
o set volume to 100 ml (DW) 
Upper gel buffer stock (4×, 100 ml): 
o 6,055 g Tris (0,5M) 
o 4 ml SDS stock 
o 80 ml DW 
o set pH to 6.8 
o set volume to 100 ml 
Acrylamide (30%, 100 ml): 
o 29 g acrylamide 
o 1 g bisacrylamide 
o 100 ml DW 
Acrylamide (40%, 100 ml): 
o 38.9 g acrylamide 
o 1.1 g bisacrylamide 
o 100 ml DW 
APS 10% (ammonium-peroxy-
disulfate): always freshly prepared! 
o 100 mg APS   
o 1 ml DW 
Resolving gel (7%, 10 ml (for 2 
gels)): 
o 2.5 ml lower gel buffer stock 
o 5.1 ml DW 
o 2.3 ml 30% acrylamide 
solution 
o 5 μl TEMEDa 
o 50 μl APS (fresh!) 10% 
Stacking gel (5 ml (for 2 gels)): 
o 1.25 ml upper gel buffer 
stock 
o 3,15 ml DW 
o 0,55 ml 40% acrylamide 
solution 
o 5 μl TEMED 
o 50 μl APS (fresh!) 10% 
Gel running buffer Stock (10×, 
500 ml): 
o 15 g Tris 
o 72 g Glycine 
o DW  500 ml 
o No SDS!!! 
Gel running buffer (400 ml): 
o 40 ml gel running buffer 
sock 
o 4 ml SDS stock 
o 300 ml DW 
o set pH to 8.3 
o DW  400 ml 
                                                 
a Always add TEMED and APS just before casting. 
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Procedure 
1) Assemble gel cassette as described by the manufacturer, and place it in the gel casting 
apparatus. Be careful to wipe the glasses clean from fat and dust. 
2) Prepare the resolving gel. 
3) Insert a comb in the cassette, and fill the cassette with resolving gel up to a level about 
2-3 mm below the comb. 
4) Overlay 0.1% SDS on top of hardening gel (so as not to dry out). Wait at least 
30 minutes. 
5) Prepare stacking gel 
6) Discard the SDS from the top and adjust the position of the comb. 
7) Add stacking gel up to the top of the comb. The gel will shrink as it hardens. Wait 30 
minutes. 
8) Prepare samples and standards 
9) Dissolve protein samples in 100 μl of sample buffer, containing 2% mercaptoethanol 
10) Use 2 μg of standards. 
11) Incubate in 70°C waterbath for 20 mins 
12) Load the samples in the gel pockets 
13) Put gels under running buffer, and fill the slots 
14) Run the gel 200 V, 35-40 min. 
2.6.1.12Western Blot 
Materials 
Immobilon-P membrane 6x9cm 
2 Filter paper 7x10cm 
Electroblotting apparatus (Bio-Rad 
Mini Trans-Blot Cell) 
Transfer buffer: 
o 25 mM Trizma-base 
o 192 mM Glycine 
o 0.75% SDS 
TBS: 
o 2.42 g Trizma-base 
o 8.00 g NaCl 
o 3.8 ml 1M HCl (better 
solubility) 
o 800 ml DW 
o set pH to 7.6 
o fill up to 1000 ml 
0.1% TBS-Tween: 
o 1 ml Tween-20 
o 1000 ml TBS 
5% milk solution: 
o 5 g milk powder 
o 100 ml TBS-Tween 
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1st antibody solution (10000×) in 
milk (25ml/membrane is enough) 
dissolve in 5% milk. (Rabbit anti-
SOX9) 
2nd antibody solution (5000×) in 
milk (25ml/membrane is enough) 
dissolve in 5% milk. (biotinylated 
anti-rabbit IgG) 
Streptavidin-peroxidase (5000×) 
Amersham ECL Plus Western 
Blotting Detection System Solution 
A and Solution B 
Kodax X-OMAT AR film
 
Procedure 
1) Prepare 3 dishes. Put methanol in one, transfer buffer in other 2. 
2) Cut membranes, and filter papers. 
3) Prepare blotting device as described by the manufacturer. 
4) Transfer: 250 mA, 3 hrs or 90 mA overnight 
5) Block with 5% milk solution, shaking overnight at 4 °C, or at least 1 h RT 
6) Decant the milk, do not wash! 
7) Soak the membrane in the 1st antibody-milk solution, shake for 1h. 
8) Decant the milk solution, wash 3× for 10 min with TBS-Tween. 
9) Put the 2nd antibody-milk solution on the membrane, shake for 1h. 
10) Decant the milk solution, wash 3× for 10 min with TBS-Tween. 
11) Put the Streptavidin-peroxidase solution on it, shake for 1h. 
12) Get the Solution A and Solution B (Amersham) out of the fridge. 
13) Decant the solution, wash 3 times, 10 min with TBS-Tween. 
14) Mix 8 ml Solution a with 200 μl Solution B 
15) The membranes are too wet at this stage, so get rid of the excess liquid by gently 
touching a tissue paper with one corner of the membrane. 
16) Put the membranes on a nylon layer, and soak them with the mix using a glass pipet. 
17) Wait 5 minutes. 
18) Get rid of the excess solution the same method as above. This is very important. 
19) Put the membranes in the dark box. 
20) Take the films, and expose them for appropriate time in a dark room. 
21) Develop films. 
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2.6.2 ELISA 
2.6.2.13TGF-  1 
This assay employs the quantitative sandwich enzyme immunoassay technique. A monoclonal 
antibody specific for TGF- 1 has been pre-coated onto a microplate. Standards, controls and 
samples are pipetted into the wells and any TGF- 1 present is bound by the immobilized 
antibody. After washing away any unbound substances, an enzyme-linked polyclonal antibody 
specific for TGF- 1 is added to the wells to sandwich the TGF- 1 immobilized during the first 
incubation. Following a wash to remove any unbound antibody-enzyme reagent, a substrate 
solution is added to the wells and color develops in proportion to the amount of TGF- 1 bound 
in the initial step. The color development is stopped and the intensity of the color is measured. 
Materials 
Quantikine human TGF- 1 ELISA kit (DB100B) 
1 N HCl 
1.2 N NaOH/0.5 M HEPES 
Procedure 
1) To 100 ml of cell culture supernatant, add 20 ml of 1 N HCI. Mix well. 
2) Incubate at RT for 10 minutes. 
3) Neutralize the acidified sample by adding 20 ml of 1.2 N NaOH/0.5 M HEPES. Mix 
well. 
4) Add 50 ml of Assay Diluent RD1-21 (for cell culture supernatant and urine samples) or 
Assay Diluent RD1-73 (for serum/plasma samples) to each well. 
5) Add 50 ml of Standard, control, or activated sample per well. Tap the plate gently to 
mix. Cover with the adhesive strip provided. Incubate for 2 hours at RT. 
6) Aspirate each well and wash, repeating the process three times for a total of four 
washes. Wash by filling each well with Wash Buffer (400 ml) using a squirt bottle, 
manifold dispenser or autowasher. Complete removal of liquid at each step is essential 
to good performance. 
7) After the last wash, remove any remaining Wash Buffer by aspirating or decanting. 
Invert the plate and blot it against clean paper towels. 
8) Add 100 ml of TGF-b1 Conjugate to each well. Cover with a new adhesive strip. 
Incubate for 2 hours at RT. 
9) Repeat the aspiration/wash as in step 6) 
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10) Add 100 ml of Substrate Solution to each well. Incubate for 30 minutes at room 
temperature. Protect from light. 
11) Add 100 ml of Stop Solution to each well. Gently tap the plate to ensure thorough 
mixing. 
12) Determine the optical density of each well within 30 minutes, using a microplate reader 
set to 450 nm. Subtract readings at 540 nm from the readings at 450 nm. This 
subtraction will correct for optical imperfections in the plate. 
2.6.3 Real-time RT-PCR 
2.6.3.14RNA isolation 
Materials 
TRITM REAGENT (Molecular Research Center MRC, cat. # TR-118) supplemented 
with 5 μl/ml Polyacryl CarrierTM (MRC, cat. # PC-152) 
1-Bromo-3-chloropropane (BCP, SIGMA Molecular Biology, cat. # B9673, or MRC, 
cat. # BP-151) 
Isopropanol (2-Propanol, FLUKA MicroSelect for molecular biology, cat. # 59304) 
High Salt Precipitation Solution (MRC, cat. # PS-161) (0.8 M sodium citrate and 1.2 M 
NaCl, for isolation of RNA from samples containing large amounts of polysaccharides 
and/or proteoglycans)  
Ethanol (FLUKA BioChemika, cat. # 02849) 
Diethyl pyrocarbonate (DEPC) treated water: 0.1% DEPC in deionized water (see 
PRBM 006) 
75% Ethanol in DEPC treated water 
TE Buffer: prepared from 100× concentrate (SIGMA cat. # T-9285) with DEPC-treated 
water 
Sterile polypropylene centrifugation tubes 
Procedure 
1) Cell lysis: Scaffold samples were homogenized in a 2 ml polypropylene tube, in 1 ml 
TRITM reagent and a 4 mm steel ball, using a Tissuelyser bead mill (Quiagen) at 24 Hz 
for 2 min. Tubes were then centrifuged at 7500 RCF for 5 min, and clear supernatants 
were transferred into new tubes. In case of 24-well plate monolayers, 0.5 ml TRITM 
reagent was simply added to the cells, and after brief incubation everything was 
collected into a polypropylene tube. 
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2) Samples were stored at 80°C until further isolation 
3) Phase Separation: Store the homogenate for 5 min at room temperature. Add 0.1 ml 
BCP per 1 ml of TRITM REAGENT, cover the samples tightly and shake vigorously for 
15 sec. Store the resulting mixture at room temperature for 2–15 min and centrifuge at 
12000 RCF for 15 min at 4°C. Following centrifugation, the mixture separates into a 
lower red, phenol-chloroform phase, interface, and the colorless upper aqueous phase. 
RNA remains exclusively in the aqueous phase 
4) RNA Precipitation: Transfer the aqueous phase to a fresh tube. Precipitate RNA from 
the aqueous phase by adding 0.25 ml of isopropanol followed by 0.25 ml of a high salt 
precipitation solution per 1 ml of TRITM REAGENT used for the initial 
homogenization. 
5) Store samples at room temperature for 5-10 min and centrifuge at 12000 RCF for 8 min 
at 4-25°C. 
6) RNA Wash: Remove the supernatant and wash RNA pellet (by vortexing) with at least 
1 ml of 75% ethanol per 1 ml TRITM REAGENT used for the initial homogenization. 
Centrifuge at 7500 RCF for 5 min at 4-25°C.  
7) Repeat wash. The RNA precipitate can be stored in 75% ethanol at 4°C for at least one 
week, or at least one year at –20°C. 
8) RNA Solubilization: Remove the ethanol wash and briefly air-dry the RNA pellet for 3-
5 min. Until visible liquid is not present anymore. If the pellet overdries, it is very 
difficult to dissolve. Add RNA in DEPC treated water by passing the solution a few 
times through a pipette tip and incubating for 10-15 min at 55-60°C. 
9) RNA Quantification: Measure absorbance A260 and A280. Appropriately dilute RNA 
samples in TE-buffer to obtain an absorbance A260 between 0.1 and 1.0. A260 of 1.0 
corresponds to 40 μg/ml RNA. 
10) To assess the purity of RNA, determine the A260/A280 ratio. An A260/A280 ratio of 1.6-
1.9 is expected. Protein contamination results in A260/A280 ratio <1.6. 
11) RNA can be stored in aqueous solution at 80°C. 
This protocol is based on studies by Chomczynski et al. (Chomczynski, 1993; Chomczynski 
and Mackey, 1995; Chomczynski and Sacchi, 1987) 
2.6.3.15Reverse transcription 
Materials 
200 μl-micro reaction tubes 
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TaqMan Reverse Transcription Reagents (all from Applied Biosystems, Foster City, 
CA) for 20 μl reaction volume: 
o 2.0 μl 10× TaqMan reverse transcription (RT) Buffer (polymerase chain 
reaction [PCR] Buffer II, 500 mM KCl, 100 mM Tris/HCL, pH8.3) 
o 4.4 μl MgCl2 (25 mM, #N8080010) 
o 4.0 μl Deoxynucleotide trisphosphate (dNTP) mixture (2.5 mM for each dNTP, 
#N8080260) 
o 1.0 μl Random Hexamers (50 μM, #8080127) 
o 0.4 μl RNase Inhibitor (20 U/ml, #N8080119) 
o 0.5 μl MultiScribe Reverse Transcriptase (50 U/ml, #4311235) 
o 7.7 x μl RNase-free water  
o x μl (4 pg –1 μg) RNA sample 
Thermal Cycler 9600 (Applied Biosystems) 
TE (Tris-EDTA) Buffer: prepared from 100× concentrate (SIGMA cat. #T-9285) with 
DEPC-treated water 
Procedure 
1) The reagents are stored at –20°C. Prior to use, thaw all reagents except the Reverse 
Transcriptase and the RNase inhibitor. When the reagents are thawed, keep them on ice. 
Keep also RNA samples and reaction mixture on ice. 
2) Prepare reaction mix (for sample number + 1) by combining all the nonenzymatic 
components. Mix the components by pipetting up and down, vortex briefly 
3) Add the reverse transcriptase and RNase inhibitor, put them back in the freezer 
immediately after use. Mix the components by inverting the microcentrifuge tube, do 
not vortex! 
4) Dispense appropriate volume (20 VRNA μl) into 200 μl micro reaction tubes 
5) Add RNA sample to the respective tubes. 
6) Run reverse transcription program: 10 min at 25°C for primer incubation, 30 min at 
48°C for reverse transcription, 5 min at 95°C for reverse transcriptase inactivation. 
7) Optionally dilute the resulting cDNA with TE-buffer and store at –20°C 
Based on TaqMan Gold RT-PCR Kit Protocol, Applied Biosystems, 1997 
2.6.3.16Real-time PCR 
Materials 
AB 7500 Real Time PCR System (Applied Biosystems) 
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MicroAmp Optical Tubes and Optical Caps, or  
ABI PRISM Optical 96-well Reaction Plates and ABI PRISM Optical Adhesive Covers 
(Applied Biosystems) 
Reaction components: 
o TaqMan Universal Master Mix (2× concentrated, #4324018) 
o 45 μM Forward Primer (900 nM)  
o 45 μM Reverse Primer (900 nM) 
o 12.5 μM TaqMan Probe (250 nM, 5’ FAM (6-carboxyfluorescein) and 3’ 
TAMRA (6-carboxy-N,N,N´,N´-tetramethylrhodamine) labeled 
oligonucleotide) 
o Alternatively, primers and probe can be replaced by a 20× mix by Applied 
Biosystems (TaqMan gene expression assays). 
o cDNA in deionized water 
For a complete list of primers and probes used see Table 2-4. 
Table 2-4 List of primers and probes used 













































TGFB1 GACTACTACGC GAGCTCTGATGTGT TGGTGGAAACCCACAAC
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18S Applied Biosystems #4310893E 
Procedure 
8) Prepare reaction mixture for (2n+2) reactions (n=sample number) by combining 
TaqMan Universal Master Mix, primers / probes, and deionized water 
9) Distribute into Optical Tubes or Optical Plates 
10) Add cDNA samples in duplicates, run 1 NTC (no template control) reaction without 
cDNA for each reaction mixture 
11) Cover tubes with Optical caps or plate with adhesive cover 
12) Centrifuge ~400 RCF, 30 s to remove air bubbles from the bottom of the tubes. 
13) Run PCR with following conditions on AB 7500 Real Time PCR System: 
o 2 min @ 50°C if AmpErase UNG is used 
o 10 min @ 95°C to activate DNA polymerase 
o 40 cycles of 15 sec @ 95°C, 1 min @ 60°C) 
14) Calculate Ct values by subtracting Ct values of internal control (18S) from Ct of the 
gene of interest for each sample. Relative expression can be calculated by the following 
equations: 
Ctsample= Ctsample Ctref 
Expression=2 Ct 
Based on User bulletin #2, ABI PRISM 7700 Sequence Detection System, Applied 
Biosystems, P/N 4303859 Rev. A, 1997, and TaqMan Universal PCR Master Mix, Protocol, 
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Applied Biosystems, 1998, as well as Sequence Detection Systems Chemistry Guide, Applied 
Biosystems, Part Nr 4348358 Rev. A 11/2003. 
2.7 Histology 
2.7.1 Lactate dehydrogenase (LDH) assay 
Snap-frozen samples were cut in the cryostat. They were briefly melted on the warm slide. The 
slides were then stored at -20 (inside the cryostat) until stained. 
Materials 
Disposable plastic sample holder 
Flat Styrofoam container 
Weighing boat 
Cryo-compound 
Liquid  N2 
2-methyl butane 
40% Polypep, Sigma P5115 
Lactic acid, Sigma 69771 
Nicotinamide adenine dinucleotide (NAD) Sigma 43410 
Nitroblue tetrazolium (NBT) Sigma N5514 





1) Place samples in a plastic cryo-holder and soak in the cryo-compound for at least 30 
min, up to a few hours. This is necessary in order to replace water in the sample, and so 
improve the cutting properties after freezing. 
2) Prepare liquid N2 bath in a large Styrofoam container, and fill a weighing boat with 
2-methyl butane. 
3) After the N2 bath has cooled down, lower the weighing boat into the liquid N2 carefully. 
4) Wait until the butane has cooled down, adjust sample position for cutting, and place the 
plastic holder in the weighing boat. 
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5) The cryocompound now freezes over completely. Remove the sample, and immediately 
place it in -20°C (cryostat or freezer). The samples can be stored for up to a year in an 
air-tight container. 
6) Cut the samples to 12-20 μm sections with a cryotome. 
Staining procedure 
7) Add lactic acid (5.4 mg/ml, 60 mM final) and NAD (1.75 mg/ml) to appropriate 
amount of polypep solution. Adjusted pH to 8.0 by adding 1M NaOH. Added 1 tablet 
of NBT per 3.3 ml of this solution. 
8) Draw a circle around the sections with a DAKO pen, add 100-200 μl solution per 
section. Incubate at 37°C for 4h. The viscous solution will not allow the LDH enzyme 
to diffuse away from the cell. 
9) Warm mounting medium to room temperature 
10) Warm PBS to ~37°C, and wash samples in this, until all the polypep is gone, but as 
shortly as possible 
11) Fix in 4% buf. formalin for ~20-30 min 
12) Wash in Milli-Q water 
13) Dry samples on a paper 
14) Add 1 drop of DAPI mounting medium on the slides and coverslip 
15) Observe living cells under transmitted light and all cell nuclei under blue fluorescence 
set-up. Every area can be imaged with both settings, and the image pairs can be 
overlaid later. 
2.7.2 Oil red O 
Materials 
Cell monolayers (in adipogenic medium or neg. control) 
Stock solution: 0.5 g Oil Red O in 100 ml 2-propanol 
Working solution: dilute 6 ml of stock solution in 4 ml dH2O. Mix. Wait at least one 
hour and less than 24 hours before use. Just prior to use, filter with a Whatman filter. 
Protocol 
1. Aspirate all cell culture medium 
2. Fix cells with paraformaldehyde, 1% 10 min at 4°C. 
3. Rinse with dH2O 
4. Rinse with  isopropyl alcohol, 60% for 30 sec 
5. Incubate for 10 min in Oil Red O working solution 
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6. Rinse with  isopropyl alcohol, 60% for 30 sec 
7. Rinse with  tap water 
2.7.3 Von Kossa 
AgNO3 stains organic compounds in the presence of light (UV). It can be used to stain 
mineralized tissue (Hydroxyapatite crystals mixed with organic material). 
Materials 
0.2 M Na2S2O3: 5 g Na2S2O3.5H2O (Fluka 72050) in 100 ml DW. Prepare fresh! 
5% AgNO3: 5 g AgNO3 (Fluka 85230) dissolved in DW, keep it protected from light! 
Procedure 
1) Wash monolayers 2× with PBS (or TBSS) without Ca 
2) Fix 5 min in 4% buffered formalin 
3) Wash 3× in DW 
4) Add 5% AgNO3 solution for 30 min. Keep it in (not direct) daylight (UV important!) 
5) Prepare Na2S2O3 solution. 
6) Wash 3× in DW 
7) Add Na2S2O3 solution for 5-10 min. 
8) Wash 2× in DW 
9) Add DW, or let it dry and observe under transmitted light microscope. Take both 
microscopic and macroscopic pictures, because the latter ones will help judge the 
overall amount of calcification, and prove that the microscopic pictures represent the 
whole culture and not only a small part of it. 
2.7.4 Safranin-O 
Haematoxylin is a nuclear stain, it consists of metal ions (aluminum) and haematoxylin. The 
latter is a dye extracted from the Central-American logwood tree (Haematoxylum 
campechianum). The mixture of the two is red at acidic pH. After the “bluing” with running tap 
water, the dye acquires its blue color. Safranin O is a metachromatic substance, which stains 
cartilaginous tissues orange. It does so by binding to negatively charged proteoglycans. Fast 
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o 50 g Aluminum-potassium-sulfate  
o 500 ml DW  
o 3 g Haematoxylin  
o 100 ml DW  
2nd solution 
o 50 g Chloral-hydrate  
o 500 ml DW (dissolve completely)  
o 0.2 g Sodium-iodide  
o 1 g citric acid (dissolve)  
Mix the two solutions in a dark bottle. It is immediately usable, can be stored for a long time. 
Filter before use. 
Fast Green FCF: 
0.1 g Fast Green  
Dissolve in 500 ml DW  
Safranin O: 
0.1 g Safranin O  
Dissolve in 100 ml DW  
Procedure 
10' MilliQ-water 1×
10' Meyer’s haematoxylin 1×
10' Blue in flowing tap water 1×
10' 0.02% Fast green in water 1×
10'' 1% acetic acid rinse 1×
15' 0.1% Safranin O 1×
short rinse in DW 1×
2' 70% ethanol 1×
2' 96% ethanol 2×
2' abs. ethanol 2×
short rinse in Xylene 1×
5' Xylene 1×
Coverslip with EukittTM. 
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Methanol and H2O2 
Vectastain ABC-kit EliteTM staining solutions (Vector Laboratories, Burlingame, CA) 
Primary, monoclonal antibody (1-C-6, Developmental Studies Hybridoma Bank, 
University of Iowa, Iowa City, IA) 
Secondary antibody (Vectastain ABC-kit EliteTM, Biotinylated anti-mouse, dilute 200×) 
Chondroitinase ACII 0.025 U/ml 
Procedure 
1) Cryo-sectioning is described under Lactate dehydrogenase (LDH) assay on p. 54 
2) draw circle around 20 μm thick sections with DakoTM pen 
3) 5 min rehydration in PBS-Tween 
4) Mix 100 ml methanol with 1ml 30% H2O2 and incubate sections for 20 mina 
5) Wash 3×5 min in PBS-Tween 
6) Chondroitinase AC treatment 30 min at 37 Cb 
7) Wash 3×5 min in PBS-Tween 
8) Block with 20× diluted horse serum (60 min, RT, dilute with PBS) 
9) Don't wash afterwards, just gently blot the side of the slide on a dry paper towel, and let 
it draw in most of the blocking solution 
10) Add primary antibody (diluted 6×) over night, 4°C for 12-16 hrs. Negative control 
slides receive only PBS! Incubate them in a humidified box to prevent drying out. 
11) Wash 3×5 min in PBS-Tween 
12) Add secondary antibody, incubate 30 min, RT 
13) In the meantime prepare staining solution. Store at 4 C at least for 30 min (better 
longer, prepare fresh every day) 
o 1 ml PBS (without Tween) 
o 20 l ABC-A 
                                                 
a This blocks endogenous peroxydase activity, which would interfere with the detection reaction in the end 
b Chondroitin-sulfate chains prevent epitope recognition, therefore they should be removed. In the case of scaffold 
samples, a very mild treatment is required, stronger treatment destroys the epitope. 
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o 20 l ABC-B 
14) Wash 3×5 min in PBS-Tween 
15) Apply ABC-complex prepared earlier (30 min, RT) 
16) Wash 3×5 min in PBS-Tween 
17) Add 3-30-diaminobenzidine solution for 4 min (incubate in the dark, important!) 
18) Stop reaction in tap water 
19) Counterstain with Meyer’s haematoxylin (20 s) 
20) Differentiate in tap water 
21) Dehydrate in ascending alcohol 
22) Clear in xylene 
23) Mount under coverslip with DPXTM. 
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Chapter 3 Osteogenic differentiation of MSCs 
3.1 BMP-2 delivery method 
3.1.1 Introduction 
Bone tissue heals relatively easily; moreover, the resulting tissue is mechanically more 
resistant than the original one. In other words, a fracture occurs less frequently at the site of a 
previous fracture. One may think that bone is a tissue, where tissue engineering is superfluous. 
There are cases, however, where bone healing is inadequate: most importantly in osteoporotic 
bones, and critical size defects. In osteoporosis the resorption exceeds bone formation, making 
the bones very fragile. This condition mainly affects post-menopausal women. Critical size 
defects occur at the site of ostectomy, usually performed in order to remove an osteosarcoma or 
large high impact damage. These defects do not heal spontaneously. 
We can assume that bone healing does not occur in these cases even after a long time, because 
these conditions rarely occurred in nature, especially during the reproductive part of the life 
cycle. Human lifestyle and lifespan dramatically changed in the last century; hence it may be 
necessary to artificially stimulate bone healing in problematic cases. 
Bone healing can be greatly improved by fixation and immobilization of the fracture site. 
When this surgical approach fails, autografts can used to enhance bone-healing. This procedure 
requires a second operation at the site of tissue harvest (commonly iliac crest), which increases 
the possibility of surgical complications at the site (donor-site morbidity). Therefore, allografts 
are also used. In these surgeries, there is a minimal but real risk of disease transmission from 
donor to recipient with allografts.(Centers for Disease Control and Prevention (CDC), 2001; 
Centers for Disease Control and Prevention (CDC), 2002) Additionally, 30% to 60% of 
allograft implants fail after 5-10 years.(Wheeler and Enneking, 2005) Tissue engineering is one 
possible solution. It uses graft substitutes, or matrices, which can be formed from a variety of 
materials (natural and synthetic polymers, ceramics, and composites).(Radomsky et al., 1999; 
Ripamonti, 1996; Zhang et al., 2002) Matrices can also act as delivery vehicles for factors, 
antibiotics, and chemotherapeutic agents.(Ohgushi and Caplan, 1999) 
3.1.1.17Effects of BMP-2 and its method of delivery 
The study of enhanced bone formation kicked off with a report by Urist in 1965.(Urist, 1965) 
He described new bone formation induced by a decalcified bone implant. It was clear, that 
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there must be some sort of factor that orders the host cells to form bone, and that this factor 
must be part of the acid-insoluble residue of bone powder.(Reddi and Huggins, 1972) 
Soon, several proteins with bone anabolic activity were isolated, and were called bone 
morphogenetic proteins. One of these, recombinant human bone morphogenetic protein 2 
(BMP-2) was shown to induce ectopic bone formation in rats.(Wang et al., 1990) This finding 
has been confirmed by several groups, and is widely accepted today. Clinical trials were 
carried out in order to transfer these findings into health care. The results, although promising, 
require a very high dose of recombinant protein to stimulate bone healing.(Friedlaender et al., 
2001; Govender et al., 2002) These factors are present at a very low concentration in the 
human body, it is therefore possible that the type of delivery was not ideal in these clinical 
studies, and that is why such a large dose was required. 
An alternative way to deliver BMP-2 is utilizing the host cells’ protein synthesizing capacity 
by delivering the DNA of the gene of interest into its nucleus. This can easily be achieved by 
using viral vectors. It was demonstrated, that direct intraosseous administration of adenoviral 
vectors encoding BMP-2 was able to heal critical size defects in rabbits and rats.(Baltzer et al., 
2000; Betz et al., 2006) When trying to transfer these results into a large animal model, it was 
found that the same method did not stimulate bone healing in sheep.(Egermann et al., 2006) 
In the following in vitro experiments we wanted to evaluate the applicability of sheep as a 
model for human bone healing. The effect of recombinant BMP-2 and adenovirally transduced 
BMP-2 on osteoblasts (OBs) and MSCs was investigated. 
In these experiments, MSCs were cultured in 24-well plates for 2 weeks. The medium was 
changed every 3-4 days. There were 4 treatment groups for both sheep and human cells (Table 
3-1). Samples were taken at day 4, 8 and 14. To quantify osteogenic differentiation, ALP 
activity and 45Ca incorporation were tested.  
Table 3-1 Treatment groups for BMP-2 testing experiments 
 
 
Negative Control Same as described (Osteogenic, page 19), but without dexamethasone
5 Neg.control, infected with empty virus 
AdBMP-2 Neg.control, infected with BMP-2 adenovirus 
rhBMP-2 Neg.control, with 50 ng/ml rhBMP-2 
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3.1.2 Results 
The negative control and 5 group behaved indifferently, therefore on the following graphs 
only the negative control results are shown. The presence of BMP-2 protein was confirmed by 
a specific ELISA assay. Media conditioned by AdBMP-2 transduced MSCs contained about 
50× more BMP-2 than rhBMP-2 samples. 
3.1.2.18ALP activity 
ALP activity was enhanced by AdBMP-2 treatment in the absence of dexamethasone in all 
MSC cultures by day 14 (Figure 3-1). The average increase between day 4 and day 14 was 
4.5× in human and 22× in sheep MSCs. The control ALP activity levels were stable in both 
types of MSCs. 
AdBMP-2 was also effective in the case of OBs, increasing ALP activity 14× in human and 
64× in sheep between day 4 and 14.  In addition, human OBs showed a spontaneous, 4× 
increase in ALP activity, which was delayed, compared to the immediate effect of AdBMP-2, 
and was detected between day 8 and day 14. 
The rhBMP-2 treatment did not induce higher ALP levels than control in any cell type. 
It is also noteworthy that the ALP activity of sheep cells (both OBs and MSCs) was 
insubstantial. However, when they were transduced with human BMP-2 transgene, the activity 
became comparable or higher than that of human cells. 
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Figure 3-1 ALP activity 
Data points show mean ALP activity at 3 time-points ( , dotted line - control; ×, dashed line - rhBMP; +, solid 
line - AdBMP). The gray bars represent ±1 SD (standard deviation). 
3.1.2.1945Ca incorporation 
The calcification results follow the trends observed in ALP activity. AdBMP-2 treatment 
increased calcification rate compared to control at day 21 in all MSC cultures (123× in human, 
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12× in sheep) (Figure 3-2A). It was also enhanced in human (2.5×) and sheep (3.4×) OB 
cultures (Figure 3-2B). 
When the media were supplemented with rhBMP-2, no change in 45Ca incorporation rate could 
be detected. 
Generally, MSCs had a lower initial and a higher induced calcification rate than OBs. 
 
Figure 3-2 45Ca incorporation 
The box plots summarize the amount of 45Ca incorporated overnight. The boxes contain 50% of the data points, 
the bold lines denote the median values, and circles represent outliers. **p<0.01 
3.1.3 Discussion 
The result of this study is straightforward: first it shows that AdBMP-2 cell transduction is able 
to clearly induce osteogenic differentiation in MSCs and to enhance OB function in human and 
sheep cells; second, that addition of rhBMP-2 at 50 ng/ml into the culture media fails to 
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increase ALP and matrix calcification by day 21 of culture; and third, that human and sheep 
MSCs and OBs behave very similar upon BMP-2 stimulation. 
The first finding indicating the high efficiency of AdBMP-2 cell transduction system in driving 
the differentiation of MSCs or maturation of OBs, clearly suggests that our previous in vivo 
failure to induce bone healing in sheep was most probably due to an inflammatory and/or 
immune response to the injected AdBMP-2 at the fracture site.(Egermann et al., 2006) Indeed, 
in another study, when a direct adenoviral transfer of BMP-2 was performed ex-vivo on sheep 
MSCs or OBs and then the transduced cells were re-introduced at the fracture site, an enhanced 
fracture healing was observed, indicating that lower titers of adenovirus together with a precise 
cell target population could be more efficient than directly injecting naked AdBMP-2 in 
situ.(Egermann et al., 2006) Noteworthy, both human and sheep cells (MSCs and OBs) 
responded similarly upon transduction with AdBMP-2.  
The second observation about the lack of ALP induction and matrix calcification in human 
MSCs when BMP-2 is added to the media confirms previous reports.(Diefenderfer et al., 2003; 
Jørgensen et al., 2004; Osyczka et al., 2004) Indeed, Jørgensen et al. showed that 
mineralization occurred at 6 weeks of culture without an increase in ALP activity. Therefore it 
is possible that in the present study matrix calcification could have also been observed at later 
time point of culture. Regarding the rhBMP-2 dose used in the present study, although it can be 
considered to be in the lower concentration range, other publications using higher BMP-2 
concentration have reached the same conclusion. Therefore, our and the other reports clearly 
indicate that human MSCs are not so inclined to progress towards an osteogenic differentiation 
upon rhBMP-2 exposure, in contrary to rodent and rabbit cells. Here, in addition, we show that 
sheep MSCs behave similarly to human cells in response to added BMP-2. 
The discrepancy between the two BMP-2 delivery methods could be due to different reasons. 
First, the synthesized protein after gene transfer has been shown to be more biologically active 
than the recombinant protein a as consequence of physiological post-translational 
modifications.(Olmsted et al., 2001) In addition, the biosynthesis of BMP-2 by the cells could 
also involve the simultaneous production of other important players, as BMP-2 receptors, 
BMP-2 activators and/or the decrease of BMP-2 inhibitors such noggin or chordin. 
Furthermore, in the hMSC cultures treated with AdBMP-2, the BMP-2 protein levels were 
about 50× higher than in rhBMP-2 treated ones which may explain the lack of effect when 
rhBMP-2 is added (at this concentration) directly to the media.  
In conclusion, this study suggests that adenoviral BMP-2 delivery is a feasible method to 
differentiate both human and sheep MSCs into OBs. This would suggest that the sheep is a 
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feasible large animal model of human osteogenic differentiation with respect to response to 
BMP-2 stimulation, and that previous in vivo studies failed because of some other obstruction, 
and not the irresponsiveness of sheep MSCs to adenoviral BMP-2. 
3.2 On the role of statins in osteogenic differentiation 
3.2.1 Introduction 
It may also be possible to differentiate MSCs into OBs by using chemical compounds instead 
of growth factors. 
In 1971 Akira Endo and Masao Kuroda started searching for a 3-hydroxy-3-methylglutaryl 
coenzyme A (HMG-CoA) reductase inhibitor. They assumed that certain microorganisms 
would produce such compounds as a weapon against other microbes that required isoprenoids 
for growth. Soon after, they discovered mevastatin.(Endo et al., 1976) Later, a whole family of 
HMG-CoA reductase inhibitors – natural and synthetic – was found, including lovastatin 
(mevinolin), simvastatin and pravastatin. By the 1990s many of these compounds were 
approved for clinical use: lowering cholesterol levels in blood. However, HMG-CoA reductase 
inhibitors interfere with fundamental synthetic processes in the cells, therefore their effects are 
diversified and many of those are not well characterized. (Figure 3-3) 
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Figure 3-3 The HMG-CoA reductase pathway (©GNU FDL) 
Statins are inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. The 
product of this enzyme is mevalonate, a precursor of isoprenoid pathways in cells. Isoprenoids 
are building blocks of several important, sometimes essential end-products, such as: 
farnesylated and geranyl-geranylated proteins, ubiquinone, cholesterol, and through this latter 
steroid hormones, vitamin-D, bile acids and lipoproteins.(Goldstein and Brown, 1990) The 
activity of many proteins is regulated by isoprenylation and/or addition of cholesterol.(Ghosh
et al., 1997) Statins interfere with isoprenoid production, which leads to altered protein 
synthesis.(Takemoto and Liao, 2001) 
Mevalonate, independent of the presence of cholesterol, is essential to cell proliferation. It was 
reported that lovastatin treatment caused inhibition of DNA synthesis in BHK-21 cells 
resulting in the complete elimination of the S phase from the cell cycle.(Quesney-Huneeus et 
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al., 1979) Later, lovastatin was shown to inhibit prenylation of several small GTP-binding 
proteins, thereby disturbing their function.(Ghosh et al., 1997) Prenylation enables these 
proteins to bind to the cell membrane, which is essential for their activity. One of these is 
RhoA, which has an important role in actin stress fiber assembly and cytokinesis. Others, like 
the Ras oncogenes play an important role in cell cycle regulation. Their inappropriate 
activation leads to malignant transformation.(Bos, 1989) Inhibition of these proteins explains 
the cell cycle arrest before the S phase. Simvastatin has been shown to have a toxic effect on 
pancreatic adenocarcinoma cells and mevastatin induced apoptosis in human peripheral blood 
monocytes.(Ura et al., 1994; Vamvakopoulos and Green, 2003) 
Besides modulating the cell cycle and shape, statins also reduce cholesterol production. 
Consequently, the blood low density lipoprotein levels decrease, and this prevents 
arteriosclerosis. This is a property of statins that has been utilized in the clinic with great 
success.(Tobert et al., 1982a; Tobert et al., 1982b) Statins have further beneficial effects on 
vascular walls and on platelets.(Takemoto and Liao, 2001) 
HMG-CoA reductase is a fundamental enzyme of a diversified biochemical pathway. Its 
inhibition is expected to cause many, seemingly unrelated changes in cell metabolism and 
differentiation. The influence of statins on bone mass was first reported by Mundy and 
colleagues.(Mundy et al., 1999) The effect of lovastatin and simvastatin was tested in vivo on 
rats and in vivo on rat calvarial explants. The compounds were injected subcutaneously or 
administered orally. They observed increased bone volume in the explants, and increased bone 
mass in the animals. The investigators explained this finding with two factors: inhibition of 
bone resorption by decreasing osteoclast activity and numbers, and increased osteoblast 
activity by statin-induced BMP-2 production. The latter, anabolic process was considered by 
the authors to have a greater impact on bone mass. 
Following these results, human clinical studies were conducted, where bone mineral density 
and fracture risk were the investigated outcome variables. Some studies showed a positive 
effect of statins in osteoporotic patients.(Chan et al., 2000; Pasco et al., 2002; Solomon et al., 
2005) Others showed no significant improvement at all.(Rejnmark et al., 2004; van Staa et al., 
2001; Wada et al., 2000) 
An inhibitory effect of statins on bone resorption was demonstrated recently by several 
research groups.(Hughes et al., 2007; Staal et al., 2003) They suggested that statins act on 
osteoclasts similarly to bisphosphonates, by the inhibition of farnesylation and geranyl-
geranylation of proteins, leading to inactivation of osteoclasts through cytoskeletal changes. 
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In addition, statins appear to enhance osteoblast function. Maeda et al. reported that statins 
induced the gene expression of several osteoblast markers (BMP-2, vascular endothelial 
growth factor, ALP, COL1A1, bone sialoprotein, osteocalcin) in a pre-osteoblastic mouse cell 
line.(Maeda et al., 2004) Pitavastatin enhanced bone morphogenetic protein 2 (BMP-2) and 
osteocalcin expression in primary human osteoblasts, by inhibiting Rho-kinase 
activity.(Ohnaka et al., 2001) 
These publications illustrate that statins affect a range of tissues and cell types in vivo, and that 
they may be candidates to treat different types of diseases. The aim of this study was to 
investigate the effect of different statins on the osteoblastic differentiation of primary human 
mesenchymal stem cells (MSC). Such a differentiation process has been previously shown in 
rodent and human cell lines. Simvastatin induced osteoblastic differentiation in mouse MC3T3-
E1 cells and lovastatin induced osteogenesis in the human D1 cell line. At the same time 
adipogenic differentiation was inhibited.(Li et al., 2003; Maeda et al., 2001) 
There are few reports regarding the effect of statins on primary human MSCs, and the results 
are rather controversial. Fluvastatin and simvastatin induced osteogenic differentiation in two 
separate studies.(Baek et al., 2005; Benoit et al., 2006) On the contrary, Lee et al. found, that 
fluvastatin and lovastatin promoted neuroglial, but not osteoblastic differentiation of 
hMSCs.(Lee et al., 2004) There is also disagreement between studies on rodent MSCs.(Song et 
al., 2003; Sonobe et al., 2005) 
In some of the above mentioned reports non-standard reagents or complicated cell isolation 
methods were used. Therefore we intended to clarify how unmodified, commercially available 
statins affect the osteoblastic differentiation of bone marrow derived human MSCs in vitro. 
Should statins induce osteoblastic differentiation of MSCs, they might be useful in bone tissue 
engineering applications as osteogenic factors. 
In order to investigate this, we employed the standard method for the isolation of MSCs (see 
page 16). After expansion the cells were seeded in 24-well plates, and were treated with 
different concentrations of statins. Three different statins were used; two were lipid-soluble 
(lovastatin and simvastatin), and one was water-soluble (pravastatin). These were added to the 
basal osteogenic medium (see Osteogenic, page 20) of MSC monolayers. 
3.2.2 Results 
Pravastatin had no effect on MSC differentiation based on the markers used in this study. There 
was no significant difference between pravastatin treated cultures and non-induced controls 
regarding DNA content, BMP-2 and ALP expression, ALP activity or calcification. Therefore, 
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in the following sections only the effect of simvastatin and lovastatin is discussed, and 
sometimes will be referred to as statins. 
3.2.2.20Dose dependency tests 
The first step when testing a new substance is to establish a dose-response curve, as different 
concentrations may induce very different reactions in the cells. First we tested various 
concentrations of lova- and simvastatin on the MSCs. We selected the concentrations around 1 
and 5 μM based on literature data.(Mundy et al., 1999) We found that the statins strongly 
affected cell proliferation. (Figure 3-4, p.70) After 18 days (the last time-point), we observed 
the lowest DNA content at 5 μM concentration, which was very close to the DNA amount in 
the day 0 cultures. This suggests that there was very little or no DNA synthesis in the cells. 
Lower concentrations caused a decrease in cell proliferation in a dose-dependent manner. 
 
Figure 3-4 Dose-dependent decrease in DNA amounts 
after 18 days. 
Legend: C - non-induced control, D - dexa, L - 
lovastatin, S - simvastatin. The numbers next to letters 
represent concentrations in M. 1 donor, the error bars 
show SD of triplicates (experimental error). 
We also looked at two biochemical markers of 
osteoblastic differentiation: alkaline 
phosphatase (ALP) activity (page 36) and 
45Ca incorporation (page 38). Interestingly, 
the statins were found to decrease ALP 
activity, but at the same time induced calcification at higher concentrations. (Figure 3-5A-B, 
p.71) 
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Figure 3-5 Dose-dependent reaction of biochemical markers 
(A) Suppression of ALP activity by statins at day 18. Legend: C - non-induced control, D - dexa, L - lovastatin, S 
- simvastatin. The numbers next to letters represent concentrations in M. 1 donor, the error bars show SD of 
triplicates (experimental error). (B) Increase of Ca-45 incorporation by statins at day 18. Legend: C - non-induced 
control, D - dexa, L - lovastatin, S - simvastatin. The numbers next to letters represent concentrations in M. 1 
donor, the error bars show SD of triplicates (experimental error). 
The results are intriguing, because both ALP and calcification are osteogenic markers, but in 
this case they behave differently. Also, the highest 45Ca incorporation was observed where cell 
proliferation was lowest. Based on these data we decided to further investigate this question 
with larger sample sizes. Two concentrations were chosen from lova- and simvastatin: 5 μM, 
because this is where calcification was highest in both statins; and 1 μM, because this is where 
no increased calcification was observed, but an effect on cell number and ALP activity was still 
obvious. Besides, there was a negative control group (C), basic osteogenic medium and vehicle 
only, and a positive control group (D), treated with dexa, a standard osteogenic agent. 
3.2.2.21Ca-45 incorporation 
The most important marker of fully differentiated osteoblasts is their ability to mineralize their 
own extracellular matrix. However, maturation is a lengthy process, and even if we could see 
that something may be happening, there was no significant difference between treatment 
groups after 18 days (p=0.07). This is also due to the different reactivity of cells from different 
donors. When we followed cell differentiation for 25 days, a significant difference could be 
observed. (Figure 3-6, page 72) As expected, the dexa-treated group had a higher activity than 
the non-induced control (p<0.01). At 1 M concentration simva- and lovastatin samples 
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showed a lower calcification rate (p<0.05). The median calcification values of the 5 M statin 
groups were higher than non-induced control, but the level of significance was not reached 
with these sample sizes. 
 
Figure 3-6 Calcium incorporation rates 
Values are relative to non-induced control after 25 
days, on a logarithmic scale (3-9 donors, triplicates). 
Legend: C - non-induced control; D - dexa; L1 - 1 M 
lovastatin; L5 - 5 M lovastatin; S1 - 1 M simvastatin; 
S5 - 5 M simvastatin. The box contains 50 % of the 
data points. Outliers are noted by circles. * p 0.05, ** 
p 0.01 compared to non-induced control. 
The lack of significance can also be a result of 
inter-individual variation in starting-point, 
peak and extent of calcification. Also, because 
of the poor attachment of the cells, some of the calcified layer may be detached during the 
washing step after incorporation. Even with these hurdles, the calcification was very prominent 
in some of the experiments. 
3.2.2.22BMP-2 expression 
It is widely accepted, that statins induce the expression of BMP-2, an osteogenic factor. In 
order to validate our culture system, and maintain integrity with the literature it was important 
to show this phenomenon. Indeed, statins increased the BMP-2 expression at both 1 and 5 M 
concentration by day 4. (Figure 3-7) The extent of the up-regulation varied within a wide 
range, but the positive effect is not questionable. In some cases, the negative control samples 
showed a spontaneous increase of BMP-2 by day 11 and 18, which is probably due to the basic 
osteogenic culture medium (containing ascorbic acid and beta-glycerophosphate). It is also 
noteworthy, that dexa acted the opposite way: on day 11 and 18 the BMP2 expression was 
lower than that of controls. 
















100 ** * *
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Figure 3-7 Relative amount of BMP-2 mRNA 
The three time-points are distinguished by grayscale shading. Legend: C - non-induced control; D - dexa; L1 - 1 
M lovastatin; L5 - 5 M lovastatin; S1 - 1 M simvastatin; S5 - 5 M simvastatin. Each bar represents a mean 
value of 2-6 experiments (N=2-6). All values are relative to day 4 non-induced control of the respective 
experiment, and are plotted on a logarithmic scale. The error bars span 1 SD. 
3.2.2.23ALP activity and expression, pattern 
When we further investigated 1 and 5 M statins, we found, that ALP activity was suppressed 
by statins at all time-points. (Figure 3-8) Dexa is known to promote osteoblastic differentiation 
in vitro; consequently, a marked increase in ALP activity was detected in the cells treated with 
dexa. 
 
Figure 3-8 ALP activity 
Measured with a para-nitrophenylphosphate assay at 
day 11. The amount of product was normalized to 
DNA, and compared to the activity of the non-induced 
control. Legend: C - non-induced control; D - dexa; L1  
1 M lovastatin; L5 - 5 M lovastatin; S1 - 1 M 
simvastatin; S5 - 5 M simvastatin. The error bars 
represent ±1 SD. The data are triplicates from 1-6 
donors (N=1 in case of S1). *p 0.05 compared to non-
induced control. 
The ALP gene expression followed the same 
trend, it decreased as a result of statin 
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treatment (there was only one outlier in 40 samples, Figure 3-9). This is surprising, because 
normal osteoblast function requires ALP activity. 
 
Figure 3-9 ALP expression 
Relative amount of tissue independent ALP mRNA in 
different treatment groups at three time-points 
(distinguished by grayscale shading). Legend: C - non-
induced control; D - dexa; L1 - 1 M lovastatin; L5 - 5 
M lovastatin; S1 - 1 M simvastatin; S5 - 5 M 
simvastatin. Each bar represents a mean value of 2-6 
experiments (N=2-6). All values are relative to day 4 
non-induced control of the respective experiment, and 
are plotted on a logarithmic scale. The error bars span 1 
SD. 
To find out whether it is consistent throughout 
the whole culture, one experiment was performed, where samples were taken more frequently. 
According to the results, ALP was constantly suppressed by statins, and a peak could be 
observed in the expression of ALP in the dexa samples at day 3. (Figure 3-10) 




































Figure 3-10 ALP expression time-line 
Gene expression values are relative to day 4 control. The data points are the mean values of triplicates from 1 
donor. 
3.2.2.24DNA amount and MTT assay 
Another interesting aspect of the dose-dependency experiment was the suppression of cell 
proliferation by statins. To confirm this, several experiments were performed, all yielding very 
similar results: the DNA amount was constant, sometimes slightly decreasing towards the end 
of the culture period (Figure 3-11) Low concentrations showed weaker inhibition of cell 
proliferation. 
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Figure 3-11 Relative DNA amounts  
All values are compared to day 0. The gray error bars represent standard deviation of triplicate samples from 2 
donors. * p<0.05 between control-dexa and all other treatments  
To confirm these results with a second method, cell activity was measured with MTT assay. It 
proved to be more consistent than DNA measurement (lower standard deviation) (Figure 3-12). 
This may be because – depending on the type of cell death – the DNA of dead cells can still be 
present in the wells for some time, and may or may not be washed off at media change. On the 
other hand, enzymatic activity ceases soon after cell death due to ATP depletion, and even if 
the cell body and DNA is present, it would not give a signal in this assay. 
 
Figure 3-12 Relative metabolic activity 
As determined by MTT assay at different time-points. 
All values are compared to day 0. The gray error bars 
represent standard deviation of triplicate samples from 
2 donors. † p<0.05 between day 11 and day 18 of the 
same treatment; ††† p<0.001 between day 11 and day 
18 of the same treatment 
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3.2.2.25Apoptotic staining 
Statins at 5 M clearly changed cell morphology by day 4: the cells were rounder and larger 
than the non-treated ones (routine microscopic observation). Cell numbers decreased 
significantly between the last two time-points, which suggests that cell death may occur at the 
late stages of the culture. The type of cell death (apoptotic or necrotic) was determined by 
Annexin-V-propidium-iodide combined staining. Dexa and 1 M statin samples were not 
different from non-induced control cells. Some cell death is present, probably due to high cell 
density and manipulation during the staining. Intense Annexin-V staining was observed in 5 
M statin samples at day 18 (Figure 3-13). The stained cells were large, round, and the cell 
membranes were rough. Most of these cells were not stained with propidium-iodide. Positive 
annexin-V staining is not unequivocal evidence of apoptosis, but it certainly indicates 
disruption of the cell membrane’s integrity. This may be caused by apoptosis or decreased 
amount of cholesterol or both. 
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Figure 3-13 Apoptotic staining 
Monolayers were stained with propidium iodide and fluorescein-labeled annexin V after 18 days of culture. 
Propidium (red) stains the nuclei of necrotic cells only. Green stain labels both apoptotic and necrotic cells. 
Therefore, apoptotic cells are single-stained (green), and necrotic cells are double-stained. Viable cells are not 
visible on these images. C - non-induced control; D - dexa; L1 - 1 M lovastatin; L5 - 5 M lovastatin; S1 - 1 M 
simvastatin; S5 - 5 M simvastatin 
3.2.2.26Von Kossa staining 
Both 5 M statins and dexamethasone caused mineral deposition, which was stained by von 
Kossa’s method after 25 days of culture (Figure 3-14). The staining appeared very similar 
when looking with the naked eye, however, the microscopic morphology of these deposits was 
different: in the dexamethasone-treated samples mineralization was visible in the extracellular 
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matrix and around the cells, while the statins caused strong staining only along the cell 
membranes. Non-induced control and 1 M statin samples resulted in no von Kossa staining. 
 
Figure 3-14 Calcification patterns 
Different calcification patterns in dexa (D) and 5 M simvastatin (S5) treated hMSC cultures (Von Kossa staining, 
phase contrast images) after 25 days. The overview images show the macroscopic appearance of the von Kossa 
staining in the 24-well plates. In both treatment groups, the left hand wells were decalcified prior to the staining as 
a negative control. The microscope images demonstrate characteristic morphological differences in calcification. 
The exposure time was 36 ms at both micrographs. The contrast and gamma values were modified to the same 
extent on both pictures in the ImageJ image analysis program for better visibility. 
3.2.2.27Mevalonate 
Cell death may be caused by the exhaustion of the pool of essential mevalonate-derived 
molecules (such as cholesterol) in the cells, because addition of 100 M mevalonolactone 
partially reversed the effects of statins restored the cell number and shape, and partially 
reversed the suppression of ALP activity in two independent experiments. (Figure 3-15) The 
statins lowered ALP activity to 20-30% compared to non-induced control. This effect was 
alleviated by mevalonolactone, reaching 40-80% of the control activity. 
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Figure 3-15 Rescue by mevalonate 
(A) Cell proliferation was restored by addition of 100 M mevalonate (day 18). Values are mean values of 
triplicates from 1 donor. (N=3) (B) Partial restoration of ALP activity. Values are mean values of triplicates from 
1 donor. (N=3) 
3.2.3 Discussion 
In this study we investigated the effect of three statins on primary human MSCs. It has been 
suggested that statins may promote osteoblastic differentiation of MSCs in mouse and human 
cell line.(Ohnaka et al., 2001; Song et al., 2003) These assumptions were mainly based on the 
increase in the mRNA expression of BMP 2. This was also observed in our experiments. 
However, other pronounced alterations, especially in cell morphology, suggest to us that 
prolonged exposure to statins might have a cytotoxic effect on most of the human MSCs. 
Pravastatin did not show any effect on the measured parameters of MSC differentiation, while 
simvastatin and lovastatin showed a clear long-term detrimental effect on cell viability. A 
possible explanation is that lovastatin and simvastatin are hydrophobic molecules; hence, they 
can passively penetrate the cell membranes and affect the cell’s biochemistry in an unregulated 
manner. On the contrary, pravastatin is water soluble, and it has to be actively transported into 
cells. For example, in hepatocytes the LST1 anion transporter protein is involved in this 
process.(Nakai et al., 2001) Its presence in human MSCs has not yet been investigated but this 
study would suggest that no active transport occurs. 
Simvastatin and lovastatin effectively elevated BMP-2 expression, in agreement with the 
results from previous reports. However, BMP-2 is a versatile molecule, probably because it 
plays a role in several developmental processes. It does not only promote osteoblast 
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differentiation, but chondrogenic and neuronal differentiation as well.(Lee et al., 2004) ALP 
activity – another important marker of osteoblast differentiation – was significantly decreased. 
This inhibitory effect was also observed at the ALP gene expression level throughout the whole 
culture period. The extent of down-regulation was comparable to the decrease of activity, so 
statins probably regulate ALP activity at the transcription level. 
These results are in contrast with the recent data of Baek et al.(Baek et al., 2005) In their study, 
the ALP activity was elevated during the first 6 days. Human MSCs were isolated with the 
same method in both studies, and the cells were cultured with 1 M simvastatin. However, 
there are differences, such as the composition of medium during MSC attachment and 
expansion that may explain the conflicting results. (Their expansion medium contained 
vitamins C and K, -glycerophosphate and antibiotics, in addition to higher serum 
concentration (20 % vs. 10 %). The source of statins (Merk vs. Calbiochem) was also 
different.) 
Furthermore, Baek et al. used osteocalcin as a differentiation marker which appeared within 12 
days. It is unlikely that osteocalcin would appear after 12 days in the negative control cultures, 
as it is expressed only by mature osteoblasts.(Aubin and Triffitt, 2002) This suggests that their 
MSC isolations contained mature osteoblasts, and this would readily explain the different 
outcome. 
Statins at 1 M or lower concentration showed decreased 45Ca incorporation compared to 
control samples by day 25. This can be partially explained by the slight decrease in cell number 
as shown by cell viability data at day 18; at day 25 it was not measured. 
Benoit et al. investigated the effect of 0.01 and 0.1 M polyethylene-glycol-released fluvastatin 
on human MSCs.(Benoit et al., 2006) They reported that the treatment had a short-term 
positive effect on calcium-content (4-times higher within 24 hours). Although the total Ca 
content between day 7 and 14 remained higher in the treatment group, all of this increase was 
incorporated during the first 24 hours. Indeed, between day 7 and day 14 the difference in total 
Ca incorporated diminished (1.8-times compared with 4 times at 24 hours), indicating that the 
control group had a greater Ca incorporation between these time points. This implies that low 
concentration of statins exerted a long-term inhibition on calcium deposition, which is in 
accordance with our results. 
Samples treated with 5 M statins equaled (or exceeded) the 45Ca incorporation rate of non-
induced controls despite the marked decrease in cell number and the inhibition of ALP activity. 
Sugawara et al. showed that enzymatic activity of the ALP protein is necessary for 
mineralization of osteoblastic cells in vitro.(Sugawara et al., 2002) Even though the 
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calcification pattern appeared similar macroscopically, there were marked differences at the 
microscopic level. As the structure of the deposited calcium is different in the dexa-induced 
control and the statin-treated samples, the observed mineralization may not be physiological. In 
the statin-treated cultures the mineralization is localized around the cell membranes, suggesting 
release of certain ions from the cells, which can form a precipitate with the calcium and/or 
phosphate present in the medium. Similar, cell death-related ectopic mineralization was 
described by Zimmermann et al.(Zimmermann et al., 1991) 
The considerable statin-induced changes in cell morphology (rounding and enlargement) 
support this assumption, and indicate similar cytoskeletal changes to the ones reported by 
Ghosh et al. in cultured mesangial cells.(Ghosh et al., 1997) These changes include rounding, 
loss of actin stress fibers and apoptosis. Simvastatin has also been shown to have a toxic effect 
on pancreatic adenocarcinoma cells and mevastatin induced apoptosis in human peripheral 
blood monocytes.(Ura et al., 1994; Vamvakopoulos and Green, 2003) 
Based on cell viability data and apoptotic staining images, we wish to suggest, that 5 M 
simvastatin and lovastatin have a cytotoxic effect on most human MSCs, that peaked towards 
the end of the culture period (18-25 days), causing ectopic mineral deposition. Cell death may 
be caused by the exhaustion of the pool of essential mevalonate-derived molecules (such as 
cholesterol) in the cells, because addition of 100 M mevalonolactone partially reversed the 
effects of statins restored the cell number and shape, and partially reversed the suppression of 
ALP activity in two independent experiments. The enhanced annexin-V-binding at later time-
points is also explained by this theory, since cholesterol has an important role in stabilizing cell 
membranes, which is lost by the inhibition of HMG-CoA reductase, and results in exposure of 
phosphatidylserine. 
Although the negative effect of 5 M statins on MSCs was evident, viable cells were still 
present even after 18 days. Since the initial adherent MSCs are a heterogeneous population, it 
is possible that there exists a subpopulation of cells, which is more resistant to statins than the 
others. 
A report by Lee et al. supports our study from a different perspective: they observed neuroglial, 
but not osteoblastic differentiation of human MSCs treated with high concentrations of 
fluvastatin (50 and 2 M).(Lee et al., 2004) The indicative morphological changes took place 
in the first few days of culture, and cell death was seen after longer exposure, which is in 
agreement with our observations. Furthermore, Sonobe et al. stated that statins did not induce 
osteogenic differentiation of rat MSCs at a 0.01 M concentration.(Sonobe et al., 2005) 
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Conflicting opinions in the statin literature stem from the fact that the effects may vary 
depending on species, the type of statins used, and most importantly the applied concentration. 
We examined a range of concentrations, and found that statins at 1 M or lower concentration 
decreased calcification rate compared to non-induced control, together with decreased ALP 
activity. Below 1 M statins did not exert any adverse effect on cell viability; the apoptotic 
staining was negative. This is in concert with the anti-apoptotic effect of lovastatin at low 
concentrations.(Xu et al., 2008) Higher statin concentration (5 M) caused higher calcification 
rate, but this was coupled with – and most probably caused by – extensive cell death. It is 
explained by the long-known inhibitory effect of statins on the prenylated proteins.(Ura et al., 
1994) This causes marked alterations in the cytoskeleton (rounding), and loss of attachment to 
the substrate. Anchorage-dependent cells can apoptose due to long-term exposure.(Ghosh et 
al., 1997) Antiproliferative effect is also explained by a similar effect on cell cycle-related 
proteins.(Quesney-Huneeus et al., 1979)  
Hence, these compounds should be used cautiously at high concentrations, although the toxic 
effect may be alleviated in vivo. Statins may still increase bone mass through inhibition of 
bone resorption, or increasing fully mature osteoblast’s activity via BMP-2, but they are not 
able to differentiate human MSCs into osteoblasts. The calcification is not physiological, but a 
result of cell death, and BMP-2 up-regulation alone is not sufficient to call it osteogenic 
differentiation. Therefore simvastatin and lovastatin are not suitable for bone tissue engineering 
applications as osteogenic factors due to their long-term toxic effect on MSCs. 
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Chapter 4 Chondrogenic differentiation of MSCs 
4.1 Introduction 
Articular cartilage is one of the few avascular tissues in the human body. It is localized at the 
end of long bones, and provides a low friction articulation between them, as well as load-
bearing where it is required. This unique tissue is specialized to withstand extreme mechanical 
forces. Its highly organized structure certainly plays a role in the way it does so. 
Articular cartilage develops from the mesenchymal condensation of the limb bud, which first 
turns into a cartilaginous scaffold, and with the invasion of the blood vessels it calcifies, and 
forms bone. The proximal and distal ends of the bones, however, always stay in a cartilaginous 
state; they assist the longitudinal growth as transitional cartilage. When the growth is finished, 
it transforms into permanent cartilage. 
Thus, articular cartilage is strongly related to bone. Even though they are can be clearly 
distinguished from each other histologically, they are structurally and developmentally 
inseparable. All the more astonishing are the differences between these tissues. While bone has 
different cell types responsible for anabolic, catabolic and regulatory processes, we know of 
only one type of cell, the chondrocyte, maintaining the cartilage matrix. 
There is a gradual change in the structure of the cartilage from the subchondral bone towards 
the synovium, and this also affects the morphology of the cells. Near the bone there is a 
calcified cartilage layer, followed by large chondrocytes arranged in a columnar structure, 
which – through a seemingly disorganized transitional layer – turns into a dense shield of cells 
and collagen fibers at the cartilage surface. Chondrocytes are surrounded by abundant 
extracellular matrix, and a single cell has to maintain a large volume of cartilage compared to 
other tissues. 




Figure 4-1 Articular cartilage structure 
The picture is a schematic representation of the 
microscopic structure of articular cartilage. The layers 
from top to bottom are visualized by gray shading. S 
(surface zone): contains flattened chondrocytes (green 
cells), and the collagen fibers (black lines) are parallel 
to the cartilage surface. Exposed to shear forces. M 
(middle zone): A transitional layer with round 
chondrocytes and seemingly disorganized collagen 
fibers. Rich in proteoglycans (blue blobs) D (deep 
zone): Chondrocytes are slightly larger and organized 
into a columnar structure. The collagen fibers are 
perpendicular to the surface. This layer absorbs 
compressive forces. B (bone transition): calcified 
cartilage and subchondral bone are separated by a 
tidemark. Rich in collagen type X. 
Low nutrition, elaborate architecture, harsh 
mechanical environment and loosely 
distributed cells all contribute to the poor regenerative capacity of the tissue. When damaged, 
and the lesion does not reach the bone (partial thickness defect), repair often does not occur. In 
the case of full thickness defects, cells can enter from the bone marrow through the 
subchondral bone, and form a scar tissue. This fibrous tissue lacks the typical structure of the 
articular cartilage, and has a limited ability to withstand the mechanical forces it is exposed to. 
Eventually it fails, leading to osteoarthritis. This reduces the quality of life and in more serious 
cases causes disability leading to high health-care costs to treat these patients.(Clar et al., 2005) 
The aging population of developed countries makes it even more imperative to find a solution 
to such problems, where evolution resulted in the formation of sturdy, but irreparable tissues. 
Many surgical therapies have been developed to restore the integrity of articular cartilage. They 
use either pieces of cartilage tissue (mosaicplasty) or autologous chondrocytes harvested from 
a minor load bearing area. Their drawback is that they introduce new damage sites into the 
joint. An alternative cell source is highly demanded. 
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4.1.1.28 Cells 
Mesenchymal stem cells can be acquired from various source tissues, and all are able to 
differentiate into chondrocyte-like cells. The sources include fat, synovium, cartilage surface 
layer and bone marrow (see Table 1-1, page 13). Not surprisingly, synovium and surface zone 
cartilage appear to be most determined towards chondrocytic differentiation, bone marrow is 
adequate, and fat-derived stem cells are the least competent in this respect.(Park et al., 2006; 
Sakaguchi et al., 2005) The decreased chondrogenic potential of fat-derived stem cells is 
probably a result of the lack of TGF-  receptor I expression, which can be overcome by BMP-
6 treatment.(Hennig et al., 2007) Any of these choices can be backed up with strong 
arguments. The chondrogenic commitment of synovium and cartilage is advantageous, fat is 
the most easily available (and willingly donated), and also produces large numbers of cells, 
while bone marrow is the most thoroughly studied. We opted for the latter one, because of the 
abundance of literature for comparison, and in-house experience with isolation and handling 
these cells. 
Bone marrow mesenchymal stem cells were shown to be able to differentiate into chondrocytes 
(Johnstone et al., 1998; Yoo et al., 1998); therefore they are ideal candidates to replace 
autologous chondrocytes. Recently, they were also proven to contribute to healing of non-
mesenchymal tissues as well.(Sasaki et al., 2008) When fluorescence labeled MSCs were 
injected into the blood stream of mice, they facilitated the healing of skin injuries, giving rise 
to several cell types. It has been suggested, that the tissue that holds the information necessary 
for appropriate cell differentiation. 
A surgical method, microfracture, was developed in order to exploit just that.(Steadman et al., 
2001) Basically, small perforations are created in the injured cartilage down to the marrow 
space, in order to facilitate the migration of factors and cells with regenerative capacity. 
Unfortunately, this produces fibrocartilage, the presence of which temporarily alleviates pain, 
but is functionally inadequate in the long term.  
Clearly, it is necessary to develop a repair strategy using autologous, multipotent cells, and 
introduce them in a way, that they are able to integrate well into the existing cartilage structure. 
The classical tissue engineering approach has three main components: competent cells, feasible 
scaffold, and appropriate stimuli. Using an optimal combination of these three factors it should 
be possible to regenerate any kind of tissue. However, a suitable system has yet to be 
determined. 
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4.1.1.29 Scaffold 
In the standard chondrogenic cell culture, a small spheroid of about 200’000 cells is 
differentiated into cells expressing chondrocytic markers. This model is ideal to study cell 
differentiation, and early tissue engineering trials reported partial success, but spheroid cultures 
never became a routine technique for autologous cartilage regeneration on one hand due to the 
small size of the pellets (2 mm diameter). On the other hand the surface is covered in flattened 
cells, which would reduce tissue integration. Also, the cell mass rapidly further differentiates 
into hypertrophic chondrocytes. Therefore, many groups have started to explore scaffolds that 
would support the cells, and distance them from one another, so they have better access to 
nutrients, and thus a larger cell number can be used. This may deprive them from cell-cell 
contact, such as in the mesenchymal condensation during limb development, but with 
appropriate matrix and growth factors, this environment better mimics the mature cartilage, 
than the pellet culture. 
The four most widely used scaffolds for chondrocytes are agarose, alginate, fibrin and 
hyaluronate gels. Hyaluronan gel would be an ideal choice because it is abundantly present in 
the cartilage matrix. However, its mechanical strength is inadequate; therefore it needs to be 
chemically modified – for example by cross-linking or otherwise – to reach sufficient 
consistency. It can also be used in combination with the other gel-types. 
Agarose and alginate are naturally occurring polysaccharides, which provide a neutral 
environment for the cells, and allow for the diffusion of nutrients. Chondrocytes in these gels 
produce their own extracellular matrix, to which they attach through integrins and other cell 
surface receptors. This is advantageous in case of primary chondrocytes, which are less 
anchorage-dependent than – for example – MSCs, and they produce a very cartilage-like 
matrix. 
The option we chose for our studies is fibrin. This protein gel is part of the natural healing 
response, therefore is an ideal medium to deliver cells with regenerative capacity. No immune-
response is likely to occur. Cells can be conveniently mixed with fibrinogen and will only 
solidify when exposed to thrombin. Fibrin gel is able to support the survival of the cells 
suspended in it (see Cell survival, page 102). We also planned to subject the constructs to 
mechanical stimulation, therefore it was necessary to strengthen fibrin in some way. We 
achieve this by injecting the solution into a very elastic poly-urethane (PU) scaffold.(Lee et al., 
2005) In a clinical setting, chondrogenic implants are immediately subjected to mechanical 
forces due to movement of the limbs (unless the patient’s movement is limited). If a clinical 
Chapter 4 – Chondrogenic differentiation 
88 
application is kept in mind, it is better to start with a construct, which is biocompatible and is 
able to withstand mechanical stimulation.(Grad et al., 2003) 
Currently, the main challenges in cartilage tissue engineering using human MSCs are proper 
chondrocytic differentiation, and prevention of hypertrophy. In order to overcome this, our 
group devised a fibrin-PU composite scaffold, because 3D environment is crucial for this kind 
of differentiation. The next issue is a suitable differentiation stimulus. 
4.1.1.30 Stimuli 
SOX9 
TGF- 1 is routinely used to differentiate MSCs into chondrocytes. Applied at the appropriate 
concentration (around 10 ng/ml) this growth factor will induce the expression of SOX9, a 
transcription factor, responsible for chondrogenesis. This results in the expression of 
chondrocyte-related genes, mostly structural proteins of articular cartilage. SOX9 binding sites 
have been shown in the promoter of a number of such genes, most importantly: COL2A1, 
collagen type IX alpha 1 chain (COL9A1), collagen type XI alpha 2 chain (COL11A2), 
ACAN, matrilin 3.(Bridgewater et al., 1998; Deere et al., 2001; Genzer and Bridgewater, 2007; 
Han and Lefebvre, 2008; Lefebvre et al., 1997; Rentsendorj et al., 2005) 
Mutations in SOX9 cause a severe skeletal malformation, termed campomelic dysplasia. Apart 
from anomalies of the ribs and vertebral column and bowing of the long bones, this genetic 
disorder is characterized by sex reversal of genetically male embryos in most cases. This 
suggests that SOX9 also plays a role in sex determination.(Kent et al., 1996) It has been found 
that it is essential for testis development, and so indirectly for the production of 
testosterone.(Harley et al., 2003) Chondrogenesis and testis development are apparently very 
different processes, but are regulated by the same master gene. However, not exactly the same 
way! The promoter region of the genes involved in sex determination can be activated by the 
binding of monomeric SOX9, but the cartilage-related genes are regulated by SOX9 
dimers.(Bernard et al., 2003) Therefore, in the cases when only the dimerization is hindered, 
campomelic dysplasia can occur without sex reversal. 
Intuitively, one might expect that “cartilage-specific” genes are expressed in the embryonic 
testes, because SOX9 is the coordinator of both testicular and cartilage development. It has 
been reported recently, that non-chondrocytic COL2A1 and COL9A1 is in fact expressed in the 
Sertoli cells in mice during testis development.(McClive and Sinclair, 2003) 
Another difference between testes and cartilage development is the co-factors present. Namely, 
SOX5 is present during testes development, and act in concert with SOX9. But in cartilage it is 
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a long form of SOX5 (L-SOX5) – with an extra coiled coil domain, responsible for 
dimerization – that does the same.(Lefebvre et al., 1998) This also contributes to the different 
action of SOX9. 
TGF-  acts through the transcription factor SOX9 during chondrocyte differentiation. 
However, the use of growth factors is costly. Even though they are present at a very low 
concentration in the body, in actual clinical application their recombinant forms are required at 
a dose several orders of magnitude higher. Therefore, growth factors must be produced and 
applied in large quantities, which is inefficient. It appears that using the cells as protein-
producing factories is a much more convenient option. If the gene coding for the growth factor 
is introduced into the cell, it will produce, and – in the presence of appropriate signals – secrete 
the active protein. This is much more cost-effective, and physiological delivery method for 
growth and differentiation factors. Another disadvantage of growth factors is that usually they 
have diverse effects on various cells and tissues. For example, BMP-2 plays a role in 
chondrogenic and osteogenic differentiation, but is also involved in the differentiation of neural 
tissues.(Gossrau et al., 2007) Similarly, TGF-  1 is a versatile protein, influencing 
chondrogenic differentiation, T cell activity via regulatory T cells, as well as regulates the 
activity of macrophages and monocytes.(Wahl et al., 1988; Wahl et al., 2006) All these effects 
are concentration dependent, and may be difficult to regulate within a conventional gene 
transfer construct. 
An alternative solution would be the use of cartilage-specific transcription factors, such as 
SOX9, but this concept is not without questions and difficulties either. It remains to be seen 
whether transcription factors, which exert their effect on the genomic DNA, inside the nucleus, 
can be used efficiently in tissue engineering. Also, will the activity of one transcription factor 
be sufficient to activate all the required chondrogenic pathways? In this study we aimed to try 
and harness the potential of SOX9 for chondrogenic differentiation. 
SOX9 was shown to bind to the promoter region of aggrecan and activate the transcription of 
this gene in concert with two co-factors: L-SOX5 and SOX6, members of the same protein 
family.(Han and Lefebvre, 2008) Their function as co-factors of SOX9 is redundant, and they 
are not able to induce differentiation alone; SOX9 is essential. (Smits et al., 2004) Fortunately, 
these co-factors are present in many mesenchymal cell types – including MSCs – so it is 
adequate to over-express SOX9 for differentiation.(Ikeda et al., 2004) 
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4.1.1.31 Gene transfer 
The first hurdle to overcome in case of a transcription factor is that ideally it should be over-
expressed in every cell; it is not enough to transfect only a small number of cells, like it is in 
the case of a growth factor. The reason for this is that the transcription factor proteins contain a 
nuclear transport signal, hence sooner or later they are ferried into the nucleus, and normally 
never leave the cells. In contrast, a growth factor is secreted, and stimulates not only the 
secreting cell, but also its neighbors through their cell surface receptors acting in a paracrine 
fashion. So it was imperative for us to find a gene transfer method, which will result in a high 
percentage of cells expressing the transgene. 
All gene transfer methods are built around the same theme: getting the DNA into the nucleus. 
Some use modified viruses (viral vectors), which either integrate into the genomic DNA 
(retroviral vectors) or exist as a separate sequence (adenovirus). There are several concerns 
about using these vectors in clinical applications. Retroviral vectors express the transgene in a 
very stable fashion, effectively during the whole lifetime of the cell. But they may accidentally 
integrate into the wrong place, thereby interrupting important regulatory functions and 
potentially causing cancer. Non-integrating vectors do not have this drawback, but their 
expression is transient, lasting only for a few weeks at most. They have been shown to be 
useful in some cases, and their use is less limited because of their non-carcinogenic nature. 
Adenoviruses are nonenveloped icosahedral viruses. They are composed of a protein capsid 
and double-stranded DNA. They are categorized into several dozens of serotypes, which are 
regularly present in the environment; they are partly responsible for upper respiratory tract 
infections in animals, including humans. 
Adenoviruses can be used as gene expression vectors. Their life cycle starts with the 
transcription of immediate early and early genes, the products of which in turn will replicate 
the viral genome. The early genes (E1 and E3) are therefore essential for viral reproduction and 
also for the arrest of host cell protein synthesis, but do not affect the actual entry of the virus 
into the cell. These genes can be conveniently removed from the virus, with the additional 
advantage of gaining space for the gene of interest in the space-restricted adenoviral capsid. 
The viral vector generated this way is not able to amplify in normal host cells and so, it does 
not cause a disease. A specially crafted cell line, expressing the missing viral genes is 
necessary to amplify the vectors (HEK293). 
The adenovirus uses the CAR receptor to enter any kind of cell on which this receptor is 
present. The CAR protein is expressed on the surface of MSCs, albeit at a low level.(Palmer et 
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al., 2008) The transient presence of the virus bears the additional advantage that it may 
diminish by the end of the in vitro phase of the tissue engineering process, so at the time of 
implantation it is only present in miniscule amount or not at all. The transduction efficiency 
can be largely increased by the recent lanthofection method, which is described more in detail 
on page 28. 
Nevertheless, a few clinical accidents have happened in the past using adenoviral vectors, 
which caused systemic inflammation. (Marshall, 1999; Raper et al., 2003) Their use in 
articular cartilage may be safer, however, because it is an immune-privileged tissue. Also 
transduction in an ex vivo environment will result in a lower immunological challenge than 
direct injection of viral particles in vivo. 
Other methods also use the ability of viral proteins to invade eukaryotic cells, but the viral 
DNA is eliminated, and the construct containing the gene of interest is packaged in these empty 
capsids. One of the goals of our study was to evaluate the possibility to use polyomavirus-
derived VLPs to transduce MSCs. 
Non-viral methods include lipofection, where the gene of interest is packaged in a liposome, 
which aids its penetration into the cell by fusing with the cell membrane. In another procedure, 
the DNA is linked to polycationic reagents, which mask its negative charge, and make it easier 
to bind to the negatively charged cell membrane. The mixture is then internalized by the cell 
via phagocytosis and it acts as a proton sponge in the phagosome. By buffering the pH it 
protects the DNA from enzymatic degradation, and at the same time it swells, which leads to 
the vesicle’s rupture, releasing the DNA into the cytosol, from where it is imported in the 
nucleus.(Boussif et al., 1995) Some details of this mechanism are unclear, but it is successfully 
used to transfect a range of cell types. This method shows low toxicity and relatively high 
efficiency in cell lines. 
Another, more drastic solution is electroporation. Electroporation is a well established and 
simple method in bacteria. A pulse of electric current opens channels in the cell membrane, 
through which the DNA can enter the cell. In order to successfully electroporate cells, ions 
must be removed from the solution so that electricity would pass through the cells. This is 
easier done in bacteria, than eukaryotic cells, because they tolerate the lack of ions better. This 
obstacle has been overcome, and companies offer efficient methods for electroporation (such 
as Amaxa Nucleofection), with optimized programs for different cell types. 
MSCs are particularly hard to transfect, in the beginning very poor efficiencies were reported. 
Nowadays, both electoporation (Amaxa Nucleofection) and polycationic reagents (Roche 
JetPEI) claim to achieve high transfection ratios with these cells. Next to the VLPs, we set out 
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to evaluate these as possible delivery methods for SOX9. As a backup option and positive 
control, we kept adenoviral transduction. 
4.1.1.32Mechanical stimulation 
A very important aspect of the articular cartilage environment is mechanical stimulation. The 
tissue is almost constantly under dynamic load, so we hypothesized that this is necessary for 
the stable chondrocytic differentiation of the cells. Chondrocytes are affected by both dynamic 
hydrostatic pressure and the compressive load.(Connelly et al., 2004; Elder et al., 2006) 
There are a few theories on how cells experience mechanical load. One possibility is that they 
simply sense the displacement of the extracellular matrix proteins through cell surface 
receptors (integrins).(Matthews et al., 2006) During compression a large amount of water is 
squeezed out of the articular cartilage, which creates fluid flow-induced sheer-forces, and 
leaves proteoglycans behind. These high molecular weight proteins can not leave the matrix 
because the collagen mesh retains them. Due to their negative charges, there is an electrostatic 
change in the direct environment of the chondrocytes, as well as an increased osmotic pressure. 
(Haschtmann et al., 2006; Palmer et al., 2001) Any of these changes or any possible 
combination can be responsible for the mechanotransduction in chondrocytes. 
In a future clinical therapy setting, it is conceivable that SOX9-transduced MSCs would be 
delivered into a cartilage defect to aid regeneration. In this case, after a short immobilized 
period, the patient would be allowed to move the treated joint, and later to load it carefully. 
In order to simulate such a clinical situation in vitro, we used a custom-made bioreactor, which 
is able to perform 3 directions of load on the cell-seeded PU-fibrin scaffolds: compression 
(axial loading) and 2 directions of rotation (surface motion). The contact surface is a ceramic 
hip ball, routinely used in hip replacement surgeries. See page 23 for more details on the 
experimental set-up. 
Our working hypothesis was that efficient delivery of SOX9 into the MSCs would induce their 
initial conversion into chondrocytes, but for maturation and stable differentiation mechanical 
load would be necessary. Another question was whether a transcription factor alone is able to 
set the whole chondrocyte differentiation machinery in motion. 
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4.2 Results and Discussion 
4.2.1 Transfection studies 
4.2.1.33 Viral Protein 1 Virus like particles 
VP1 is the major capsid protein of a human polyomavirus, the John Cunningham virus. The 
VP1 proteins spontaneously assemble into VLPs, and they are able to encapsulate DNA, RNA 
or other macromolecules. These particles were also shown to bind and enter into human and 
monkey kidney cells, as well as the cells of the adaptive immune system.(Goldmann et al., 
1999) The particles were able to ferry these molecules into the nucleus. Our goal was to test 
whether VLPs were able to transfect human MSCs with high efficiency. 
In the following experiments we compared human MSCs with COS7 cell line as a positive 
control (derived from African green monkey kidney cells). Three types of nucleic acids were 
used to determine the efficiency of these vectors. First, fluorescence-labeled RNA was 
packaged in the VLPs, and the construct was used to track the binding and entry of the vesicles 
into the cells by laser scanning microscopy. 
Second, a plasmid containing a cytomegalovirus promoter (CMV)-driven luciferase enzyme 
(pCMVGLuc) was introduced to determine to extent of transfection, nuclear translocation and 
ultimately expression. It is a highly sensitive method, but it does not give information 
regarding the percentage of transfected cells. Hence, as a third measure, we also introduced a 
plasmid containing GFP (pmaxGFP), which remains inside the cells, and can be visualized by 
fluorescence microscopy and quantified by flow cytometry. 
This series of experiments were carried out with the help of a group of experts in Bad 
Langensalza, Germany, where we had the opportunity to use an already optimized protocol. 
This involved the use of optimized amount of cells, VLP-DNA ratio as well as a “helper” 
transfection reagent, PEI-transferrin. The detailed description of the experimental protocols can 
be found in section VLP on page 25. 
The fluorescence labeled RNA was able to bind to the cells, which is shown by the co-
localization on the fluorescence microscope images. (Figure 4-2) PEI alone was able to deliver 
RNA to the cells, causing bright fluorescence along the cellular bodies.  Interestingly, VLP 
dimmed the fluorescence. One explanation is that they optically cover the RNAs. Alternatively, 
as VLPs encapsulate the RNAs, their combined size is larger than that of a single labeled RNA 
molecule. This allows the binding of fewer fluorescent molecules per area unit, due to their 
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larger effective size. Because of the lower density of fluorescent molecules, the overall 
brightness is lower. 
 
Figure 4-2 Co-localization of fluorescent RNA and cells 
Phase contrast (left column) and fluorescence images of MSCs incubated with fluorescein isothiocyanate labeled 
siRNA. The RNA was delivered with the help of PEI-transferrin (top row) or PEI-transferrin and VLPs (bottom 
row). The scale bars are 200 μm. 
It has been found that VLP+PEI efficiently targeted MSCs with nucleic acids, but it was not 
clear whether the particles only bind to the cells, or actually enter into the intracellular space. 
We used laser scanning microscopy (LSM) to investigate this. The cells were cultured and 
incubated with the particles on a chamber slide. The optical section of containing the plane of 
the slide could be found by the largest fluorescent surface of cells, because they were spread 
out on the slide. Also, considerable amount of fluorescent debris (unbound RNA) settled on the 
surface of the slide. The tip of the cells could be also detected, because – starting from the slide 
– this was the last optical section where there was still fluorescent cell parts detectable. The 
middle of the cells was defined as the optical section half way between these two designated 
sections. 
It was found that typically, the density of fluorescent particles was similar at the bottom section 
with or without VLPs. However, the cells showed a higher and more uniform fluorescence 
distribution in the middle section when using the VLPs. Localization along the cell membrane 
was often observed in the PEI only samples. It may indicate that PEI+VLP treatment facilitates 
the internalization of nucleic acids compared to PEI only. 
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Figure 4-3 Intracellular localization of VLPs 
Representative LSM images of MSCs incubated with PEI-transferrin (left column) or PEI-transferrin and VLPs 
(right column). The images in the first row are optical sections from the plane of the chamber slide (bottom), 
while the 2nd row contains optical sections from the middle of the cells. Scale bars are 50 μm. 
To verify whether VLPs have a beneficial effect on transfection efficiency, Gaussia luciferase 
protein was delivered into the cells, and the conditioned cell culture supernatant was collected. 
The negative control (no transfection) and the VLP only medium showed no luminescence at 
all (Figure 4-4). All the other media, where pCMVGLuc plasmid and PEI-transferrin were 
present, showed considerable luminescence. All VLP treatment groups showed increased 
luminescence compared to no VLP group, even if only fifth of the DNA was added. When the 
same amount of DNA was added (VLP 5 group), the supernatants showed about 1.5× higher 
luminescence. Since luminescence detection is extremely sensitive, this increase can be 
considered insubstantial.  
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Figure 4-4 Luciferase activity 
The bars show the activity of the luciferase protein in the different treatment groups relative to pure PEI-DNA 
treatment. Error bars represent standard error. N=3 
In order to quantify efficiency, a GFP-containing plasmid was transfected into the MSCs. 
Fluorescence microscopy images of the cultures show that the treatment worked in positive 
control (COS7) cells (Figure 4-5). Fluorescent COS7 cells could be found in every randomly 
taken image. However, positive MSCs were extremely scarce; no cells appeared in the random 
fields. Fluorescent cells had to be actively searched for, and were present only in a very low 
number. In the view of the extremely poor efficiency, flow cytometry quantification was not 
required. 
 
Figure 4-5 Transfection with GFP 
Images were taken 2 days post-transfection at random locations of the ~75% confluent monolayers. Images of the 
cells were taken under identical optical setup. Exposure time of COS7 cell images was 236 ms, and MSC images 
Chapter 4 – Chondrogenic differentiation 
97 
1300 ms. The insert at the top-right corner shows proof-of-transfection image of two MSCs, which could not be 
found randomly. 
Altogether, the experiments confirmed that gene transfer into MSCs could be enhanced by 
VLPs, but the increase was practically insignificant compared to using PEI-transferrin alone. In 
spite of using an optimized protocol, the efficiency was so poor, that it would not be sufficient 
for our purpose even after vast improvement (which is unlikely to occur). After further 
optimization for MSCs, the method may become useful for delivery of DNA encoding secreted 
proteins or siRNA. For the delivery of SOX9, a different approach was clearly necessary. 
4.2.1.34 Electroporation 
Amaxa’s nucleofection technology is an effective way to deliver nucleic acids into mammalian 
cells. Briefly, it is based on the fact that appropriate electric current can create pores in the cell 
membrane (and possibly in the nuclear membrane as well), through which the DNA can enter 
the cell. A simple impulse works very well in bacteria, but it is not as efficient in eukaryotic 
cells. In this case a more complex electroporation program is needed. Amaxa has developed 
several of these programs for different cell types. Even with these very effective protocols 
another problem remains: the viability of the cell decreases significantly when they are 
exposed to electricity. The purpose of this experiment was to optimize the conditions for MSCs 
by reducing cell death and increasing electroporation efficiency. 
U23 and G22 are two electroporation programs recommended for MSCs by Amaxa. A simple 
comparison was made using the pmaxGFP plasmid and the conditions recommended by the 
manufacturer. Briefly, the cells were trypsinized, washed twice PBS, centrifuged 100 RCF, 
10 min, at 4°C then resuspended in transfection solution at 0.5 or 2.5 million cells per 100 l. 
Then, 1 ml was transferred into a cuvette, 2 g DNA was added, and different transfection 
programs were applied. White foam appeared on the top of the solution, which indicates 
denaturation of proteins, and cell death. The cells were suspended in 1 ml DMEM 20% FBS. 
The mixtures were incubated in a 6-well plate in an incubator for 2 hours before they were 
observed under the microscope. The cells were detached from the wells, and resuspended in 
PBS. Cells (total and fluorescent) were counted on a flow cytometer. 
The evaluation shows that firstly, the cell retrieval was poor (Figure 4-6). This happened even 
in the negative control groups, and may be explained by the very mild centrifugation, which is 
necessary to protect the cells. The electroporated groups generally showed a worse survival 
rate, G22 program being more protective than U23. 
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The two cell batches showed a very similar pattern in terms of both survival and efficiency. 
Cooling down the reaction did not achieve the desired benefit, and resulted in both decreased 
retrieval and transfection. Out of the two electroporation programs examined, G22 resulted in 
better cell survival (~90% of negative controls), but its transfection efficiency stayed below 
50%. The default U23 method resulted in >60% transduction efficiency, but the survival rates 
were only about 2/3 of the negative controls, which indicates that the procedure caused severe 
cell death. Higher cell number did not benefit cell retrieval, and was slightly disadvantageous 
to transfection efficiency. 




Figure 4-6 Cell retrieval 
and transfection 
efficiency using Amaxa 
Nucleofection 
The first graph shows the 
number of retrieved cells 2 
days after transfection as a 
percentage of the original 
cell number. The second 
graph shows the amount of 
fluorescent cells as a 
percentage of the total 
retrieved cells. The 4 
treatment variables are 
represented as follows. 
Cell batch: D1 and D2 are 
cells from 2 different 
donors. They are separated 
by dashed lines. B cells 
were used as negative 
controls (white bars, below 
the lower dashed line) 
Temperature: Black 
borders represent 
experiments carried out at 
RT; ice-cooled groups are 
shown by bars without 
borders. Electroporation 
programs: G22 is shown 
by light gray bars, U23 is 
dark gray. Cell number: 25 
and 5 million cells are 
shown in pairs, below each 
other.  
Cell retrieval
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In conclusion, none of the transfection methods proved to be efficient enough to be used with a 
transcription factor, which requires a very high transfection rate. The most efficient was the 
MSC specific electroporation procedure, which reached a reasonable transfection rate. 
However, it has several drawbacks: The number of cells that can be used in the transfection is 
limited, and the transfection reagents are rather costly. Also it requires millions of cells to be 
produced, very few of which actually survive and are transfected. In a tissue engineering study 
a large number of cells is needed routinely. Transfecting tens or hundreds of millions of cells 
with any of the commercially available kits is both more inconvenient – because of time 
requirements – and less effective than adenoviral transduction. The substantially higher cost of 
transfection was also an important factor at our decision to apply adenoviral transduction on 
primary human MSCs.  
4.2.2 Adenoviral Transduction 
Adenoviral vectors can be used to transduce many eukaryotic cell types, including MSCs. 
These cells, however, are more difficult to transduce than cell lines. To reach close to 100% 
efficiency, an enhancement was necessary. This can be achieved by adding LaCl3 to the viral 
solution (Transduction (Lanthofection), page 28). Fluorescence microscopy was used for 
qualitative and flow cytometry for quantitative evaluation of ideal LaCl3 concentration and 
MOI. 
The virus solution was applied at the recommended 100 MOI concentration, and serially 
diluted further in 5× dilutions steps. In Figure 4-2 the first two dilutions are presented, because 
the others were of almost undetectable efficiency. In the same experiment LaCl3 was applied at 
3 different concentrations. Based on the acquired images we concluded that lanthanum works 
well at all three concentrations examined, enhancing transduction efficiency in a very 
convincing way. We chose a concentration of 100 μM for further studies, because 200 μM 
caused a small amount of cell death in high virus concentration cultures. 
The combination of lanthanum and high virus concentration not only increased transduction 
efficiency, but also the fluorescence intensity of individual cells. Increasing transduction 
efficiency inevitably causes more virus particles entering per cell, thereby enhancing 
fluorescence. For this reason the exposure times had to be adjusted accordingly. 
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Figure 4-7 Optimization of lanthofection 
Subconfluent monolayers of MSCs were transduced with different lanthanum (rows) and virus concentrations 
(columns). Images were taken with identical optical setup. Exposure times depending on virus dilution: 1× 35 ms; 
5× 107-208 ms; 25× 1350 ms. The scale bar on the top-left image is 200 μm. 
Quantification by flow cytometry confirmed what was observed by fluorescence microscopy 
(Figure 4-8). With increasing MOI of AdGFP virus, both the percentage and the fluorescence 
intensity of the transduced cells increased. The intensity in the MOI 100 group was in fact 
outside the range of the flow cytometer (with visible negative peak). 
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Figure 4-8 Quantification of transduction efficiency 
MSCs were lanthofected with different viral concentrations at 100 μM lanthanum concentration. The graphs in the 
top row show the distribution of fluorescence intensity, the bottom row shows fluorescence intensity as a function 
of particle size. The graphs were recorded with an amplifier gain necessary to visualize the negative peaks. This 
resulted in the accumulation of virtually all events at the 1000 point on the 100 MOI graph (top-right corner). That 
is why there are no visible points at the mid-range values. The percentages below are the percentage of positive 
cells as determined by the arbitrary limit RN1 (top row). 
Because efficiency was a crucial point in our experimental setup, we decided to employ the 
safest solution, and use 100 μM LaCl3 in combination with 100 MOI virus concentration. As it 
can be observed in the bottom right corner graph of Figure 4-8, the number of small particles 
considerably increased under these conditions. This suggested to us, that cell death and/or 
shedding of small vesicles may occur, hence, it was important to determine whether these cells 
survive such intense transduction and subsequent transfer to a 3D environment. 
4.2.3 Cell survival 
In order to test our hypotheses, it was necessary to establish a feasible 3D cell culture method 
for human MSCs. We chose our custom-made fibrin-PU scaffolds and serum-free medium as 
boundary conditions. Using serum-free medium is a necessity, because successful in vitro 
chondrogenesis required chemically defined serum-free culture conditions.(Yoo et al., 1998) 
Other parameters had to be optimized most importantly to support cell survival in the 
composite scaffolds after transduction, as well as to enable chondrogenesis. Stem cells are 
routinely expanded in low-glucose MEM medium with 10% FBS, but chondrogenic culture is 
carried out in high-glucose DMEM without serum, and with different additives (page 20). It 
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was important to see if the cells would survive with this medium in a 3D environment. As a 
first attempt, pure fibrin gel with 2 million MSCs was used and cultured for 2 weeks in MEM 
or DMEM with equal glucose concentration (4.5 g/l). The outcome was determined using 
calcein-ethidium combined live-dead staining, and the DNA content of the gels was measured 
after PK digestion with the Hoechst method. Both methods showed that DMEM maintains 
slightly more cells, but both media are feasible for long-term MSC culture. Finally, DMEM 
was chosen because of better comparability with other studies, since this is the standard 
medium. 
This experiment revealed that the calcein-ethidium method has a drawback in 3D culture 
environment: many of the cells are double-stained, even though the live and dead staining 
should be mutually exclusive. It is possible – for example – that the cell membrane becomes 
more permeable because of the attachment to the ECM. To find a definitive answer whether the 
cells survive or not, an alternative method was necessary. The LDH (page 54) assay is based on 
the activity of lactate dehydrogenase, an enzyme which is active in living cells (and about 1 
day after cell death).(Stoddart et al., 2006) This way it is possible to determine which cells 
were alive 24 hours before the staining. The MSCs were cultured in fibrin-PU sponges for 21 
days and were exposed to full experimental conditions (with/without viral transduction, 
with/without mechanical loading). Next, they were snap-frozen, cryo-sectioned into 20 m 
sections and stained unfixed with the LDH reagents. 4',6-diamidino-2-phenylindole (DAPI) 
was used as a counter-stain, which visualizes the nuclei of all the cells. After coverslipping, the 
sections were observed under a fluorescence microscope. This assay proved that most of the 
cells survived under our experimental conditions for at least 20 days. The cell numbers seemed 
slightly lower than day 0, however these images are neither quantitative, nor statistically 
representative. 
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Figure 4-9 Cell viability staining 
LDH staining was performed at day 0 (A and B) and day 21 (C and D). Images were taken at the edges (A and C) 
and the middle (B and D) of the scaffolds in order to estimate cell distribution. Metabolically active cells are 
stained dark purple (black), and cell nuclei are false-colored red. The red arrow shows the nucleus of a dead cell 
(without dark cytosol staining). 
The quantitative analysis (Figure 4-10A) showed that about 95% of the day 0 DNA content 
was detected at day 21. It was concluded that the cell viability was reasonably good, and 
further, anabolic analysis could follow. 
It was important to look at the anabolic activity of the cells, because it shows how well they 
perform in this environment. A good measure of this is OHP production. This amino-acid is 
produced through post-translational modification of proline, and almost exclusively present in 
collagens. We found that our constructs produced this compound in abundance (Figure 4-10B) 
Starting from 0 g at seeding time, the cells continuously increased the amount of OHP within 
the constructs, and by the third week, they reached 40-50 g on average. By convention, this 
means 44-fold more total collagen production. The resulting 2 mg collagen is about 1% (w/w) 
of the 200 mg construct. 






























































Figure 4-10 DNA (A) and OHP (B) content within the scaffolds 
The values were measured at seeding time and after 1, 2 and 3 weeks of culture. The red line shows the value at 
seeding time. 
4.2.4 EACA 
Because of good manageability and its role in the natural healing process, the fibrinogen-fibrin 
system is a logical choice for scaffolding and delivery agent for cells with regenerative 
capacity. The components of the tissue engineering design can be conveniently mixed with 
fibrinogen and will only solidify when exposed to thrombin. 
Fibrin, however, degrades very rapidly in the presence of plasmin, which is produced by many 
cell types.(Uhlén et al., 2005) While the removal of the clot is desirable during tissue healing, 
it is a drawback in the tissue engineering process. Thus, protease inhibitors must be applied in 
studies longer than a few hours. 
A commonly used inhibitor is aprotinin. It is a polypeptide, routinely isolated from bovine 
lung. This competitive inhibitor blocks the active site of serine proteases such as trypsin, 
chymotrypsin, kallikrein and plasmin. The isolation is quite costly, and the purity of the 
resulting polypeptide is limited. Furthermore, it is not very specific to plasmin, but also 
interferes with other proteins.  
There exists a simpler inhibitor, EACA, which is a lysine-analog. It promotes the dissociation 
of plasmin, thereby inhibiting the activation of plasminogen and subsequent 
fibrinolysis.(Prentice, 1980) Apart from plasmin it is known to affect Carboxypeptidase B and 
a component of the complement system.(Dessaint et al., 1979; Soter et al., 1975) The 
production of this simple compound is inexpensive, and the effective concentration is fairly 
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low. Altogether, EACA appears to be suitable for use in fibrin-based constructs for cartilage 
tissue engineering, and it has been used for this purpose before.(Connelly et al., 2004) 
However, a study by Huang et al reported that aprotinin and EACA influenced the 
transforming growth factor beta 1 (TGF- 1) induced chondrogenic differentiation of rabbit 
bone marrow mesenchymal stem cells.(Huang et al., 2007) In order to use this inhibitor, we 
needed to see whether it influences the same process in human bone marrow mesenchymal 
stem cells. 
We decided to employ chondrogenic pellet culture for two reasons.(Johnstone et al., 1998; Yoo
et al., 1998) Firstly, this is a widely accepted method to induce chondrogenic differentiation, 
and secondly, using a fibrin gel would not allow the comparison with an un-treated control, due 
to the rapid degradation of fibrin. 
Briefly, the monolayer-expanded bone marrow cells were trypsinized and 200’000 cells were 
spun down in 15 ml polypropylene conical tubes in chondrogenic medium. Three experimental 
groups were established: non-induced control, chondrogenic control (non-induced + 10 ng/ml 
rhTGF- ) and EACA (chondrogenic control + 5 M EACA). The micromass cultures rounded 
up into a firm, round pellet overnight. These were harvested after 14 and 21 days. The 
conditioned medium was also collected for analysis. For more detailed description and 
procedures, see section Chondrogenic on page 20. 
TGF- 1 efficiently induced chondrogenic differentiation in the pellet cultures. The pellet size 
proved to be a good marker of enhanced anabolic activity (Figure 4-11). The TGF- 1-treated 
pellets were significantly larger than the non-induced controls. EACA did not influence the 
pellet size. 




Figure 4-11 Pellet size variation 
Transmitted light images of all pellets were 
acquired at the same magnification. The areas of 
the pellets’ projections were calculated with the 
ImageJ image analysis program, and are plotted 
relative to non-induced control. Each group 
contained 8 pellets from the same donor. The 
error bars represent ±SD. The projections of the 
largest and the smallest pellets are shown under 
each group. The scale bar in the bottom right 
corner is 1 mm. Legend: Non-induced – pellet 
without TGF- ; Chondrogenic – TGF- 1 induced; 
EACA – Chondrogenic + EACA 
Gene expression analysis demonstrated 
that the expressions of chondrogenic 
genes ACAN, COL2A1 and SOX9 were 
increased by TGF- 1-treatment, as was 
the hypertrophic marker COL10A1. None 
of these genes showed any response to 
additional treatment with EACA (Figure 4-12). 
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Figure 4-12 Gene expression patterns 
The relative gene expression of chondrogenic and EACA pellets are shown compared to non-induced control (fold 
increase on a logarithmic scale). The different shadings represent different genes, the error bars are located at 
±SD. N=6 Legend: Chondrogenic – TGF- 1 induced; EACA – Chondrogenic + EACA 
There was no difference in GAG release into the medium between any of the treatment groups. 
The TGF- 1-treated pellets retained 2-3× more GAGs than the non-induced group, but addition 
of EACA – again – did not cause a significant difference (Figure 4-13 and Figure 4-14). 
 
Figure 4-13 GAG production 
GAG amounts were measured in the medium (orange) and in the pellets (grey). They were both normalized to 
pellet DNA content. GAG/DNA is shown relative to chondrogenic control. The error bars represent ±SD. 
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Nmedium=15, Npellet=7, *p 0.05 Legend: Non-induced – pellet without TGF- 1; Chondrogenic – TGF- 1 induced; 
EACA – Chondrogenic + EACA 
 
Figure 4-14 Safranin-O/Fast green staining images 
Pellets were stained with Safranin-O, Fast green and Mayer’s haematoxylin. A – non-induced control; B – 
chondrogenic; C – EACA. The scale bar is 500 m. The red staining shows the localization of negatively charged 
proteoglycans, the dark blue areas are rich in collagens and cell nuclei are also stained blue. 
Based on these positive findings we decided that EACA could be used as a fibrin inhibitor in 
the following experiments. 
4.2.5 Combination of SOX9 and mechanical load 
After effective adenoviral transduction was established (Figure 4-8, page 94), it was necessary 
to confirm the effective translation and functionality of the resulting protein. Production of 
visible GFP was a positive indicator, but SOX9 presence and functionality was still to be 
tested. It was completed by western blotting for SOX9 protein and gene expression analysis of 
SOX9 target genes after transducing MSCs. Both assays were positive, which made further 
investigations possible. 













Figure 4-15 Proof of SOX9 presence and activity 
A) .Western blot for SOX9 protein. MSCs were non-transduced, transduced with AdGFP (neg. control) or with 
SOX9. A strong band is visible above 75 kDa, which is the expected size of the protein. Faint bands above and 
below are non-specific binding of the polyclonal antibody. B) Gene expression of three genes in AdGFP and 
AdSOX9-tranduced MSC monolayers relative to non-transduced control after 1 week. 
The results of this pilot experiment indicate that functional SOX9 protein is present in the 
MSCs. This allows for further investigations and combination with mechanical stimulation. 
4.2.5.35 Experimental setup 
MSC monolayers were transduced with AdGFP or AdSOX9, or were not transduced (see 
Lanthofection, page 33). Then, they were seeded onto fibrin-PU scaffolds and cultured for 6 
days without stimulation, between day 7 and day 14 (8 days) with surface motion, and in the 
last 6 days with surface motion and dynamic compression (see Loading, page 23). Gene 
expression, GAG and hydroxyproline production and DNA amount was analyzed after 6, 14, 
and 20 days. Other differentiation markers were determined at day 20. The cell culture medium 
did not contain any known chondrogenic factors. This was necessary so that we could 
investigate the chondrogenic effect of SOX9 transduction and mechanical load in order to 
mimic the in vivo situation. There were 6 treatment groups as shown in Table 2-2 on page 23. 
In the first two experiments, no difference was found in any of the markers between non-
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transduced and AdGFP controls, therefore only AdGFP control was used in later experiments 
because of limited space in the bioreactor. 
4.2.5.36Gene expression 
Mechanical loading consistently induced the expression of the lubricating protein PRG4 
compared to non-loaded controls by week 3 (p  0.01). (Figure 4-17) 
COL10A1 was also up-regulated by mechanical load about 4-fold (p  0.01 GL and SL 
compared to GN). (Figure 4-17) SOX9 had no significant effect on these genes, but it did 
influence some other important cartilage markers. 
The SOX9 expression of AdGFP samples was stable throughout the culture. In the AdSOX9-
treated samples, it was expressed at a 100-fold higher level by day 6, and was still about 10-
fold higher at the last time-point (Figure 4-16). The gene expression of its two co-factors, L-
SOX5 and SOX6, were strongly associated with SOX9 expression. (Figure 4-18) The lowest 
Ct values are those of the samples taken 1 week after transduction, when SOX9 expression 
was still very high. With the progress of the cell culture, the SOX9 expression decreased, and 


























































Figure 4-16 Gene expression of SOX9 
Boxplots show the expression of the SOX9 gene relative do day 20 GN. The numbers after the group 
abbreviations represent the sampling day (after weeks 1, 2 and 3). AdSOX9 samples (SN and SL, blue) were 
expressed significantly higher than AdGFP samples (GN and GL, green) at all time-points (p<0.05). N=10, 5 
donors 
The expression of this so-called SOX trio is restricted to cartilaginous tissues in a mouse 
embryo.(Lefebvre et al., 1998) The binding of SOX9 and at least one of SOX6/L-SOX5 is 
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necessary and adequate for the expression of COL2A1, COL11A2, and ACAN.(Bridgewater et 
al., 1998; Genzer and Bridgewater, 2007; Han and Lefebvre, 2008; Liu et al., 2007) Our 
finding is an exciting addition to this model: the over-expression of SOX9 alone resulted in 
increased levels of both L-SOX5 and SOX6. We identified several instances of the 7 bp SOX-
binding consensus sequence (C T/A T T G T/A T/A) in the 5’ upstream region of L-
SOX5/SOX6. These putative binding sites are located at the following positions in human: 
2124 and 764 basepairs before transcription start site of SOX6; and 2149, 1736 and 224 
basepairs before the transcription start site of SOX5. The SOX6 sites are conserved among 
primates and the SOX5 sites among Euarchontoglires (including rodents, rabbits and primates). 
This suggests that they may have an important function in the regulation of these chondrogenic 
transcription factors. Further promoter analysis is necessary to prove that SOX9 affects its co-
factors directly through these binding sites. 
In turn, the higher level of the SOX trio caused the increased expression of its well-known 
chondrogenic target genes. COL2A1 was up-regulated 100-1000× by SOX9 transduction after 
3 weeks (p  0.05). (Figure 4-17) Aggrecan expression was also increased about 100× by 
AdSOX9 treatment compared to AdGFP control (p  0.05, Figure 4-17) in this fibrin-
polyurethane cell culture system in the absence of exogenous TGF-  or dexamethasone. The 
expression of cartilage-specific genes was stable throughout the 3-week culture period, which 
suggests that the amount of active SOX9 protein was adequate to enhance the expression of 
these genes. 
One of the genes investigated, COMP, was affected by both treatments in an additive fashion. 
As shown in Figure 4-17, both mechanical load and SOX9 increased the expression of COMP. 
When applied together, the expression was further increased, but only to an extent what would 
be expected if the two treatments acted independently. This pattern is explained by previous 
experimental evidence regarding COMP regulation, because it was shown to be regulated by 
both SOX9 and load in independent experiments.(Liu et al., 2007; Smith et al., 1997) 
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Figure 4-17 Expression of cartilage marker genes 
Gene expression was determined after 3 weeks. Data are represented relative to GN control samples. **p<0.01, 
*p<0.05 N=10 (N=8 in case of ACAN and COL2A1) 



















































Figure 4-18 Correlation of SOX9 expression with L-SOX5 and SOX6 expression 
Correlation between the Ct values of SOX9 and L-SOX5 (left) and SOX9 and SOX6 (right) N=64, 3 donors, the 
correlation is highly significant (p<0.001). Each point represents a cell-seeded construct. The symbols correspond 
to the four treatment groups:  AdGFP, no load; + AdGFP, load; × AdSOX9, no load; * AdSOX9, load. 
4.2.5.37GAG production 
 
 Figure 4-19 Total GAG content of scaffolds 
The GAG amount is expressed relative to day 20 GN 
samples, because of the inter-individual variability of 
the results. No significant differences were found 
between groups. N=5, error bars represent ±SD 
The GAG content of scaffolds and media was 
determined after each sampling. The GAG 
amount within the sponges did not show 
significant difference between the treatment 
groups. ( 
 Figure 4-19) A scaffold contained about 40-
50 μg GAG on the average, which means that the GAG concentration within the scaffold was 
about 250 μg/ml. The concentration of GAGs in the medium was much lower, usually between 
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equal volume of conditioned medium. This is a combined effect of the fibrin-PU scaffold and 
the yet immature matrix produced by the cells. The frequent media changes may have played a 
role in maintaining this difference as well. 
The culture media volume was 3 ml (vs. 0.2 ml of the scaffold), and it was changed every other 
day. As a result, the GAGs in the medium become more important when the cumulative 
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Figure 4-20 Cumulative GAG production 
Total GAGs produced are shown as a sum of GAG retained in the sponges (dark gray bars) and GAGs released 
into the medium (light gray bars) up to the respective time-points. These are representative results from one 
experiment. 
This graph suggests that scaffolds have only a limited capacity to withhold proteoglycans. In 
this case an imaginary line can be drawn at around 45 μg. Even though GAG production 
continued up to the last time-point, the scaffolds did not accumulate more GAGs than that. As 
the pre-culture period was 6 days only, the cells were probably not able to produce an 
adequately abundant and mature extracellular matrix, which could withhold much of the newly 
synthesized proteoglycans. 
It is also noteworthy that loaded scaffolds have slightly less retained and more released GAG. 
A possible explanation is that the samples were taken shortly after loading. This stimulation 
can simply squeeze the GAGs out of the sponges, and this may result in the observed values. 
It is also apparent that the SL groups starts out with the least GAGs at day 6, but in the end it 
reaches far higher values than all other groups. The difference seems to stem from the higher 
amount of GAGs in the medium. Looking at the more representative results by averaging GAG 
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content of media from 5 experiments, the picture is similar (Figure 4-21) This implies that the 




























The graphs show the amount of GAGs in the 4 treatment groups released up to 1, 2 and 3-week time-points. The 
error bars show ±SD. N=5 
Since GAG content was determined after each media change, it is very easy to draw a plot of 
the GAG release rates (Figure 4-22). As the GAG amount within the scaffolds was less 
variable, this gives some indication about the GAG production. 
Figure 4-21 GAG release 

























Mean values are from 5 experiments. 
First, the AdSOX9-treated groups were less active at day 3 and day 6, which is in good 
correlation with the observations made before (Figure 4-21). The non-loaded groups (dashed 
lines) released GAGs at a steady rate throughout the whole culture period. 
On the other hand, the loaded groups showed more variation. They exhibited a rapidly 
increasing GAG release rate at the beginning of the first loading period up to day 8, after which 
the rate dropped. In the case of GL, it sank to the levels of non-loaded controls, while SL 
remained slightly higher. At the start of the second loading period (additional compression) 
their release rates surged up again. The GL samples’ activity decreased soon after, while the 
SL samples stayed high up to the last time-point. 
The pattern observed at the GL samples can be explained by the “squeezing” theory: there was 
a large increase when the loading intensity changed (no load  surface motion; and surface 
motion  additional compression), but it always fell back to a base level after the reserves in 
the scaffolds were exhausted. The more intense loading is able to remove more proteoglycans 
from the scaffold than the preceding milder regime. Therefore, the pattern can be a result of a 
steady production of proteoglycans and mechanical load. 
In the case of SL samples, however, the load-induced increase did not fall back as much as in 
the GL samples, especially towards the end of the culture period. It could be interpreted as a 
genuine increase in the production of sulfated GAGs. In order to prove this theory, it was 
necessary to examine the rate of sulfate incorporation by the MSCs. 
Figure 4-22 GAG release rate 
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The cell culture medium was radiolabeled with 35S-containing sulfate. After incubation, large 
molecular weight compounds from the supernatant and PK extract of the scaffolds were 
analyzed for 35S content. (Figure 4-23) The results confirmed the hypothesis described above; 
The SL group showed double the GAG production rate than all other groups. The GAG release 
rate also doubled in the same experiments, which suggests that it is indeed a good indicator of 










































Relative 35S incorporation rates at day 21 (A), and GAG release rates at day 20 (B) in the same two independent 
experiments. Error bars span ±SD, *p<0.05, N=6, from 2 donors. 
Neither mechanical load, nor SOX9 over-expression alone was able to induce increased 
production of sulfated GAGs. Only the combination of the two treatments was effective. Based 
on the high expression of ACAN, an increased GAG production rate is expected in the SOX9-
treated samples. However, it was only observed in the group where the SOX9 over-expression 
was combined with mechanical loading. This poses many questions: Is there something that 
hinders the SOX9 effect in the non-loaded group? Is GAG sulfation inhibited? Or does SOX9 
make the cells more sensitive to mechanical stimulation? We tried to answer these questions 
through different experiments. 
4.2.5.38Inflammatory cytokines 
It has been reported that high expression of inflammatory cytokines can be responsible for 
lower expression and lower activity of -1,3-glucuronyltransferase 3 (B3GAT3), which in turn 
causes deficient glycosylation.(Gouze et al., 2001) This enzyme transfers the glucuronic acid 
on the 4-saccharide linkage region of O-linked polysaccharides, such as chondroitin-sulfate 
Figure 4-23 35S incorporation rates 
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(CS) (see Figure 4-24). B3GAT3 was also shown to be the rate-limiting and essential enzyme 
of GAG synthesis in hamster ovary cells, because its involvement in producing the common 
linkage region.(Bai et al., 1999) If this enzyme is inhibited by inflammatory cytokine IL-1 , no 
glycosylation of proteoglycans occurs, and this would reduce the sulfated GAG production, 
because sulfation occurs after glycosylation. 
 
Figure 4-24 Cartilage proteoglycan structure 
Schematic representation of the proteoglycan fraction of the cartilage extracellular matrix. The left-hand picture 
shows the long hyaluronan chain with aggrecan molecules attached to it. The top-right enlarged portion shows a 
single aggrecan unit with its main structural domains. The bottom-right inlet represents the tetrasaccharide GAG 
linkage region, with the B3GAT3’s site of action. Abbreviations: HA – hyaluronic acid; G1, G2 and G3 – 
aggrecan globular domains; KS – keratan sulfate; CS – chondroitin sulfate; Ser-O – serine residue; Xyl – -D-
xylose; -D-Gal – galactose; Glc – glucuronic acid; B3GAT3 – the arrow points to the enzyme’s site of action 
We chose to investigate the expression of two inflammatory cytokines: IL1B and CCL3 based 
on a report by Gouze et al, as these were the genes most affected by the inflammation inducing 
treatment and therefore we expected larger differences in their expression.(Gouze et al., 2006) 
No significant difference was found between the treatment groups. (Figure 4-25) There was a 
trend towards lower expression of IL1B in the SL group, but it did not result in the decreased 
expression of B3GAT3. In the study by Gouze et al., decreased B3GAT3 message resulted in 
lower sulfate incorporation. Possibly the apparent decrease in IL1B levels was not strong 
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enough to allow for up-regulation of B3GAT3. There may be other – unknown – regulators 
that suppress the B3GAT3 levels independently of IL1B. 


























































The boxplots show the gene expression in the different treatment groups at day 20. No significant difference could 
be found. N=6  
However, the lack of statistical significance in the inflammatory cytokine and B3GAT3 gene 
expression data indicated that an alternative explanation is more likely. Most probably, there 
was no real problem with the glucuronidase activity, and the B3GAT3 levels were adequate for 
sulfated GAG synthesis. In this case, the cause of the beneficial combined effect must be 
sought elsewhere. 
Figure 4-25 Expression of inflammatory cytokines
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4.2.5.39TGF-  1 production 
Next, we addressed the question whether SOX9 potentiates the cells to mechanical stimulation, 
and how this effect is transmitted. The best candidate for this role is TGF- 1, because this 
growth factor has been shown to induce the expression of several cartilage-specific genes, and 
was also suggested to participate in mechanotransduction.(Johnstone et al., 1998; Li et al., 
2009; Neu et al., 2007; Yoo et al., 1998)  
TGFB1 expression was elevated by mechanical load in our model system, while another 
TGF-  isoform often associated with chondrogenesis, TGFB3 remained unaffected by 
stimulation. Thus isoform 1 is more likely to be associated with the effects of mechanical 
stimulation, than isoform 3. Looking at the extent of TGFB1 up-regulation, it is very similar in 
the two loaded groups (2-3× on the average), with the SL group appearing slightly – but not 
significantly – higher. According to these values, the GL group should be similarly affected 
like the SL group, but in terms of GAG production, it is similar to negative controls. 





































Figure 4-26 Expression of TGF-  isoforms 
The boxplots show the gene expression of chondrogenic TGF-  isoforms relative to GN controls after 3 weeks. 
*p<0.05 
The protein concentration of TGF- 1 provides explanation to this. While the gene expression 
was increased in both loaded groups, it was only translated to increased protein concentration 
in the SL treatment group. (Figure 4-27) Regardless of treatment group, the TGF- 1 
concentration strongly correlated with GAG release rate. (Figure 4-28)  
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Figure 4-27 TGF- 1 protein concentration 
TGF- 1 protein amounts relative to GN at the same time-point. (Medium was conditioned for 2 days) *p<0.05, 
error bars represent ±SD 
























Figure 4-28 Correlation of TGF- 1 concentration and GAG release rate 
The concentration of TFG- 1 and the GAG release rate were determined from media samples collected at the 3 
week time-point. Media were conditioned for 2 days. N=42, 4 donors, the correlation is highly significant 
(p 0.001). The symbols represent the four treatment groups. 
4.3 Conclusion 
Altogether, SOX9 was able to initialize the chondrogenic differentiation of MSCs in the 
absence of exogenous chondrogenic factors and dexamethasone in vitro. To achieve this, 
additional mechanical stimulation was necessary. This can be beneficial to the activation of the 
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whole differentiation process, and helps to unleash the potential of the transcription factor. 
Endogenous TGF- 1 appears to play a major role in this process. These findings confirm the 
feasibility of a cartilage repair strategy, where stem cells over-expressing SOX9 would be 
delivered into a cartilage defect. During the rehabilitation procedure, an appropriate 
mechanical loading regime would help their chondrogenic differentiation, and hopefully the 
production of integrating, stable articular cartilage tissue. 
The majority of the produced proteins (proteoglycans) was not retained, but released into the 
culture medium. This is most probably due to immature matrix, hence further optimization of 
the procedure is necessary. During an in vivo situation the matrix retention may be improved 
by the use of a membrane overlaying the implant. In vitro the culture time can be prolonged to 
allow for more abundant collagen matrix, which can help retain the functionally important 
large aggregating proteoglycans. In a recent study, where fibroblasts were used to fabricate 
vascular grafts for haemodyalisis, it took 6-9 months to produce mechanically adequate matrix 
in vitro.(McAllister et al., 2009) 
Further improvement can be reached by increasing the cell density of the scaffolds. Lately, we 
showed, that using 5 million instead of 2 million cells increases chondrogenesis in the presence 
of exogenous TGF-beta1 and dexamethasone.(Li et al., 2008) When no exogenous factors are 
used 2.5× higher cell number would result in higher concentration of endogenous growth 
factors, such as TGF-beta1, which in turn can stimulate better chondrogenesis. Very high cell 
density would result in the lack of nutrition in the central part of the construct (such as in pellet 
culture), therefore balance must be found. 
The upregulation of SOX9 in the experiments was well beyond physiological; the values 
reached 1000× increase above base level. In pellet culture, which is currently the most widely 
accepted model of chondrogenic differentiation, SOX9 expression is increased only about 10-
fold as a result of TGF-beta and dexamethasone (Figure 4-12, page 108). The high SOX9 level 
is a consequence of the high transduction efficiency. When applying a large MOI in order to 
get every cell transduced, some cells receive several virus particles, which results in very high 
transgene expression. To overcome this potentially harmful phenomenon, the CMV promoter-
driven construct could be engineered to lower the SOX9 protein production, for example by 
altering the Kozak-sequence in the promoter region. 
The results of this study prove the potential of over-expressed transcription factors in 
differentiating stem cells for tissue engineering, but also show their limitations. The SOX9 
transcription factor was able to stimulate chondrogenic differentiation of human MSCs on the 
gene expression level, but certain aspects of protein production remained unaffected. 
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Additional mechanical stimulation was necessary to achieve increased production of 
proteoglycans. Nevertheless, the study provides a stable point of reference for further 
improvements in this area. 
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Chapter 5 Conclusion 
In these studies we have investigated potential application of MSCs in tissue engineering of 
two closely related mesenchymal tissues: bone and cartilage. One of the great challenges in 
today’s tissue engineering is the proper differentiation of the competent stem cells. This is not 
only difficult to achieve, but also, it should be done in a way that can later be translated into a 
clinical application. 
This is why the osteogenic potential of statins caused great excitement.(Mundy et al., 1999) 
These compounds were already in use, and they held the promise of an easy way to tissue 
engineer bone from MSCs. Soon, numerous – positive and negative – results were reported. 
Our investigations revealed that simvastatin and lovastatin both increased the expression of an 
osteogenic marker BMP-2, but at the same time, caused apoptosis. This suggests that the 
increased BMD observed in some clinical studies may be a result of decreased bone resorption 
rather than increased synthesis. Alternatively, the overall in vivo effects may be different to that 
seen in vitro due to the presence of many different cell types.  
Differentiation factors can also be synthesized by the cells themselves. This is what we 
investigated in the next part of the study. Adenovirally introduced BMP-2 was not effective in 
a recent in vivo sheep study. We set out to compare the way sheep and human cells react to this 
growth factor. We found that they reacted very similarly, both were irresponsive to 50 ng/ml 
rhBMP-2 and differentiated into OBs using the adenoviral transduction. This tells us that there 
are other causes behind the failure of gene therapy in vivo, for example strong immune 
response to the vector. 
Finally, we tested the gene delivery approach with the SOX9 transcription factor in order to 
stimulate the chondrogenic differentiation of MSCs. This study provided us with new insight 
into some SOX9-regulated genes, and also confirmed that SOX9 regulates its own co-factors, 
SOX6 and L-SOX5. The overall outcome suggests that this transcription factor alone is not 
able to fully differentiate MSCs into chondrocytes, and additional stimulation is necessary. 
Overall, gene delivery seems to be the most effective and least harmful way to direct MSC 
differentiation. We have the right techniques for in vitro investigation of transcription factors, 
but greater care and new, more effective transfection methods are necessary for their in vivo 
application.  
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